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1. INTRODUCTION 
 
1.1 Pulmonary circulation 
 
1.1.1 The discovery of the pulmonary circulation                 
The first description of the pulmonary circulation was provided by Galen in the 2nd century, 
who said that the blood reaching the right side of the heart went through invisible pores in the 
septum to the left side of the heart where it mixed with air to create spirit and then was 
distributed to the body. According to Galen’s views, the venous system was completely 
separate from the arterial system, except when they came in contact by the invisible pores 1. 
However, Ibn Al-Nafis in the 13th century stated that the blood had to arrive from the right 
side of the heart at the left side without any direct pathway between them. He thought that the 
thick septum of the heart was not perforated and did not have invisible pores as Galen said. 
He further hypothesized that the blood from the right side of the heart had to flow through the 
pulmonary artery to the lungs, spread through its substances, mix with air, and pass through 
the pulmonary vein to reach the left side of the heart. In the description of the anatomy of the 
lungs, Ibn Al-Nafis said the lungs were composed of three parts, the bronchi, the branches of 
the pulmonary vein, and the branches of the pulmonary artery, all of them connected by loose 
porous flesh. Then he added, the function of the pulmonary artery was to transport the blood 
to the lung. Therefore what leaked through the pores of the branches of this vessel into the 
alveoli of the lungs could mix with air. The mixing process occurred in the left cavity of the 
heart 2. Later, in 1553, Michael Servetus wrote in his book “Christianismi Restitutio” that air 
mixed with blood was sent from the lung to the heart through the arterial vein and therefore, 
the mixture was made in the lungs. In 1543, Andreas Vesalius explained in his book “De 
Fabrica”, the pulmonary circulation in a manner similar to previous Ibn Al-Nafis’ description. 
An interesting observation is that in the first edition of the book, Vesalius agreed with Galen 
that the blood soaked through the septum from the right into the left ventricle. Then in the 
second edition (1555), he deleted the above statement and wrote instead: “I do not know how 
the blood pass through the septum from the right to the left ventricle” 3. Then William 
Harvey, in 1628, demonstrated in animal experiments the movement of blood from the right 
ventricle to the lung and he observed the blood returning to the left side of the heart via the 
pulmonary vein and therefore he concluded that there were no pores in the interventricular 
septum.  
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1.1.2 Physiology of the pulmonary circulation                         
The main function of the pulmonary circulation is to deliver oxygen to the blood and free it of 
carbon dioxide. This aim is achieved when the blood flows through the lungs. The walls of 
pulmonary arteries and veins are significantly thinner than the walls of corresponding vessels 
in the rest of the body. Therefore, the pressure in this part of the system is only about one-
sixth as that in the systemic circulation. In the pulmonary circulation, the roles of arteries and 
veins are the opposite of what they are in the systemic circulation: Blood in the arteries has 
less oxygen, while blood in the veins is oxygen-rich. The circuit starts with the pulmonary 
artery, which extends from the right ventricle and carries blood with low oxygen content to 
the lungs. In the lungs, it branches into two arteries, one for each lung, and then into arterioles 
and capillaries. The gas exchange between the inhaled air and the blood takes place in the 
pulmonary capillaries. Their walls act as filters by allowing molecules of gas but not 
molecules of fluid to pass through. The total surface area of the capillaries in the lungs ranges 
from 500 to 1.000 square feet. The carbon dioxide is removed from the blood in the 
pulmonary arteries across capillary walls and leaves the body through the mouth and nose. 
The blood that has picked up oxygen returns to the heart through four pulmonary veins into 
the left atrium. 
 
1.1.3 Pulmonary circulation and hypoxia  
More than 100 years ago, Bradford and Dean in the UK had described the effects of hypoxia 
on the pulmonary circulation 4. However, scientific interest in this field only started with the 
discovery of hypoxic pulmonary vasoconstriction (HPV) in the cat by von Euler and 
Liljestrand in 1946, and in man a year later in Andre Coumand’s laboratory 5. Despite the 
extensive research in this field for more than 50 years, we still do not completely understand 
the mechanism of HPV or why the response of the pulmonary vasculature to hypoxia is 
diametrically opposite to that of the systemic circulation. As lung and systemic vessels have 
different functions, lung vessels collecting oxygen while systemic vessels distributing it, most 
systemic vessels of adult organisms dilate during hypoxia, pulmonary vessels, however, 
constrict. In the isolated, buffer-perfused lung, HPV is activated when partial pressure of 
oxygen (PO2) becomes <100 mmHg 6.  
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1.1.3.1 Hypoxic pulmonary vasoconstriction (HPV)   
 
1.1.3.1.1 Principle          
HPV is a physiological self-regulatory response to alveolar hypoxia that distributes 
pulmonary capillary blood flow to areas of high oxygen availability. This principle, also 
known as the von Euler-Liljestrand mechanism, thereby optimises gas exchange at the blood-
air interface 7.  
 
1.1.3.1.2 Anatomic site of HPV         
It was initially proposed, that the main site of vasoconstriction is located at the primary site of 
gas exchange, the alveoli. Angiographic visualization of the pulmonary vasculature during 
acute hypoxia demonstrated a decrease in diameter of small pulmonary arteries, but an 
increase in caliber of the larger proximal vessels, suggesting that the small arteries or 
precapillary pulmonary arteries are the major site for acute hypoxic pulmonary response and 
that the site of oxygen sensing is not exclusively located in the alveolar capillaries 8. In 1966, 
Kato and Staub provided a histologic confirmation that the major site of hypoxic 
vasoconstriction is the small muscular pulmonary arteries at the level of the terminal 
respiratory bronchioles using the rapid freezing technique of hypoxic lung segments 9. 
Nagasaka et al. (1984) determined the microvascular profile in the feline lung during 
normoxia and hypoxia in a variety of experiments using the technique of micropuncture of 
subpleural vessels and they discovered that the predominant site of hypoxic vasoconstriction 
is within the arterial segment (30-50 µm) 10. From all these experiments, it was concluded that 
the major site of hypoxic vasoconstriction locates in the small pulmonary arteries (30-50 µm), 
with only minor increase in vascular resistance arising from the capillary bed and the venous 
system. Several studies, including micropuncture experiments 10, and isolated perfused lung 
experiments 11, demonstrated small changes in venous pressure during hypoxia compared to 
the arterial segment. Therefore, the pulmonary veins probably make a small contribution to 
the increase in vascular resistance during hypoxic vasoconstriction. Even if they constrict 
(which is possible) they do not necessarily contribute to peripheral vascular resistance.      
 
1.1.3.1.3 Mechanism(s) of HPV    
The exact mechanism(s) by which a decrease in oxygen pressure is sensed and translated into 
vasoconstriction in the pulmonary circulation is still not completely elucidated. 
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Vasoconstriction is achieved by myosin light chain phosphorylation. When intracellular 
calcium concentration ([Ca2+]i) increases, it binds to calmodulin and this complex activates 
myosin light chain kinase causing phosphorylation of the light chain of myosin. Then myosin 
binds to actin filaments causing contraction. This reaction is adenosine triphosphate 
dependent. The duration of contraction is modulated by the activity of myosin light chain 
phosphatase (MLCP) which dephosphorylates the light chain of myosin leading to relaxation. 
Inhibition of the activity of MLCP prevents the dephosphorylation of myosin light chain and 
allows for sustained calcium-independent contraction. MLCP activity is regulated partially by 
RhoA/Rho kinase pathway. Activation of RhoA/Rho kinase leads to inactivation of MLCP 
even when [Ca2+]i decreases. Sustained activation of RhoA/Rho kinase pathway is central to 
the calcium sensitization that maintains vascular tone 12. Both, MLCP by an intracellular 
calcium increase, as well as calcium sensitization, have been made responsible for HPV 13. 
The intracellular calcium increase might be achieved by release of calcium from intracellular 
stores and by influx of extracellular calcium through L-type calcium channels and non-
specific cation channels 14. Hypoxia does not cause vasoconstriction in absence of 
extracellular calcium, demonstrating that influx of calcium is critical 15. However, L-type 
channel blockers do not completely inhibit hypoxia induced vasoconstriction suggesting that 
calcium enters through other pathways 16.  
Recently, a subtype of the transient receptor potential (TRP) channels has been shown to be 
essential for acute HPV. Acute hypoxia induces PASMCs depolarization by inactivation of 
voltage-gated potassium channels on the cell membrane, that might lead to the influx of 
extracellular Ca2+ through the voltage-dependent Ca2+ channels 15. The mechanism by which 
the TRP channels are activated remains to be elucidated. Concerning the initial signal for 
activation of calcium and potassium channels there are currently several hypotheses, 
including an increase or decrease of reactive oxygen species originating from mitochondria or 
NADPH oxidases, changes in redox state due to decreased oxygen levels or an AMP-kinase 
dependent mechanism. During sustained HPV Rho-kinase might be activated by ROS 17 or 
vasoconstrictor signals, including those mediated by G protein-coupled receptors and receptor 
tyrosine kinases 18. 
Several reports have shown that hypoxia can cause contraction of isolated PASMCs 19 and 
this would appear to suggest that HPV is a function of the smooth muscle and does not 
involve the endothelium. However, whereas some reports have described HPV in isolated 
pulmonary arteries following disruption of the endothelium 20, other studies have shown that 
the endothelium is definitely required, certainly for sustained vasoconstriction 21-23. Most 
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reports, especially those on isolated cells, tend to describe processes that occur during the first 
10-15 min. However, isolated pulmonary arteries show a biphasic response to hypoxia when 
observed over longer periods 24, 25. Also, the biphasic response to sustained hypoxia has been 
described in isolated lungs 26. This biphasic response consists of a rapid, transient increase in 
vascular tone over about 5-10 min (phase 1), which then eventually falls, but does not reach 
the baseline. This is followed by a more slowly developing sustained increase in tone (phase 
2), which reaches a plateau after about 40 min. Whereas the phase 1 constriction is relatively 
unaffected by removal of the endothelium, phase 2 is abolished, the endothelium does not 
affect [Ca2+]i during the sustained phase, but releases factor(s) that sensitize the contractile 
apparatus of the SMCs to calcium 23, 27. Acute HPV is mediated by increase of calcium ion 
concentration in PASMC, while sustained HPV was shown to rely on a calcium sensitization 
of the myofilaments, possibly via phosphorylation by Rho-kinase 25, 28, 29. It would seem that 
the second sustained phase of constriction in isolated arteries is more relevant to physiological 
HPV than the transient first phase.  
 
1.1.3.2 Effects of chronic hypoxia                          
The effects of chronic hypoxia occur when the alveolar oxygen tension remains below the 
threshold for pulmonary vasoconstriction of approximately 75 mmHg. This degree of chronic 
hypoxia is obviously seen at high altitude and also can occur in other conditions like chronic 
bronchitis, emphysema and hypoventilatory states. It was found, that the most prominent 
effects of chronic hypoxia besides vasoconstriction are structural changes in the terminal 
portions of the pulmonary arterial tree 30 and polycythaemia 31 which contribute to the 
maintenance of chronic hypoxic pulmonary hypertension. The most striking effect of alveolar 
hypoxia is muscularization of pulmonary arterioles < 70 µm. Most pulmonary arterial vessels 
of this diameter normally contain only a single elastic lamina without any smooth muscle. The 
smooth muscles of these arterioles are distally extended causing the small pulmonary 
arterioles to develop a distinct media with smooth muscle sandwiched between an inner and 
an outer elastic lamina. It still remains unclear how these pulmonary arterioles come to be 
muscularized. It is unlikely to be the result of work hypertrophy because these vessels have no 
muscle in normal subjects and hypoxic vasoconstriction occurs in vessels proximal to these 
arterioles. Once pulmonary arterioles become muscularized they can constrict in response to 
hypoxia and vasoconstriction moves to a more peripheral site in the pulmonary vascular tree 
32
.  
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Additionally, chronic hypoxic exposure increases intimal thickness by causing hypertrophy 
and hyperplasia in both endothelial and subendothelial layers. Endothelial cell hypertrophy is 
associated with an increased number and size of cell organelles, including ribosomes, rough 
endoplasmic reticulum, and golgi apparatus.  
The vascular alterations resulting in hypoxia-induced PH are caused by several mechanisms. 
Chronic hypoxia increases the sensitivity of the contractile apparatus to Ca2+ to mediate 
vasoconstriction. Myofilament Ca2+ sensitization through the activation of RhoA/Rho kinase 
(ROK) and consequent inhibition of MLCP is considered the main pathway in the vascular 
smooth muscle contraction during sustained HPV, as described above, but also during chronic 
hypoxia 33. The effect of chronic hypoxia via ROK was confirmed by using Y-27632, a ROK 
inhibitor, where the mean PAP and total pulmonary resistance in chronic hypoxia-induced PH 
were drastically reduced 34.    
Hypoxia has been shown to increase the production of reactive oxygen species (ROS) such as 
superoxide anion and hydrogen peroxide in rat PASMCs 35, 36 and endothelial cells 37. ROS 
are important modulators of vascular tone and act as second messengers to activate a variety 
of intracellular signalling cascades including RhoA/ROK 38. A detailed description of 
endothelial pathways regulating hypoxia-induced PH is given in the chapter 1.3.1. 
Another effect of chronic hypoxia, subsequently to muscularization of pulmonary arterioles 
and pulmonary hypertension, is cardiac hypertrophy and failure of the right heart. Cardiac 
hypertrophy is an increase in the mass of the contractile and ancillary proteins of the heart 
above normal. The heart responds to pressure overload by hypertrophy in the form of wall 
thickening and a reduced cavity size. In its initial stages, the hypertrophied ventricle is able to 
compensate in the face of increased workload, however in the later stages, the systolic and 
diastolic properties become impaired and consequently fail to compensate leading to heart 
failure. In the hypertrophied heart, the heart cells start to die and this myocyte necrosis is 
associated with fibroblast proliferation and expansion of the extracellular matrix. Heart failure 
can be defined as the inability of the heart to provide the metabolising tissues with enough 
nutrients 39.  
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1.2 Pulmonary hypertension (PH)  
 
1.2.1 Definition                
PH is defined as a group of diseases summarized in Table 1 according to the most recent PH 
World Symposium at Dana Point and is characterized by a progressive increase of pulmonary 
vascular resistance leading to right ventricular failure and premature death.  
 
1.2.2 Classification                   
Classification of PH is necessary to facilitate the diagnosis and for determination of the lines 
of treatment. The first classification was proposed in 1973 at an international conference on 
primary PH endorsed by the World Health Organization (WHO) Symposium which classified 
PH into two categories depending on the known causes. Primary Pulmonary Hypertension 
(PPH) was classified as a separate entity of unknown cause and Secondary Pulmonary 
Hypertension (SPH) with identifiable causes 40. The updated classification from the second 
World Symposium on Pulmonary Arterial Hypertension (PAH) in Evian, France, 1998, 
focused on the clinical presentation, pathophysiological mechanisms, and therapeutic options 
41
. This was a simple classification aimed to provide a useful guide for the clinician in 
evaluating PH patients and developing treatment plans. In 2003, the third World Symposium 
on PAH held in Venice, Italy, proposed some modifications to the Evian classification 42. In 
this modification, the term “primary pulmonary hypertension” was replaced with “idiopathic 
pulmonary arterial hypertension (IPAH)”. In addition, the pulmonary capillary 
hemangiomatosis and pulmonary veno-occlusive disease were reclassified and risk factors 
were updated. Moreover, the guidelines for the classification of congenital systemic-to-
pulmonary shunts were also included. The most recent classification was proposed during the 
fourth World Symposium on PH held in 2008 in Dana Point, California, which is listed in 
Table 1 43. 
According to this classification, PH can be associated with lung disease and/or hypoxia 
(group 3), which shows validity of the experimental model of hypoxia-induced PH for 
occurrence of disease in human. However, as current guidelines for diagnosis and treatment 
are only applicable for PAH (group 1), it is referred to in the following chapters as this 
subgroup of PH. Furthermore, the New York Heart Association (NYHA) functional 
classification for heart diseases established a new functional classification (Table 2) 44. The 
NYHA classification was successful for comparison of the patients regarding the clinical 
severity of the disease state.  
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1. Pulmonary arterial hypertension (PAH)  
    1.1 Idiopathic PAH 
    1.2 Heritable 
        1.2.1 Bone morphogenetic protein receptor type 2 (BMPR2) 
        1.2.2 Activin receptor-like kinase type 1 (ALK1), endoglin (with or without hereditary  
                 hemorrhagic telangiectasia) 
        1.2.3 Unknown 
    1.3 Drug- and toxin-induced 
    1.4 Associated with 
        1.4.1 Connective tissue diseases    1.4.2 Human immunodeficiency virus (HIV) infection     
        1.4.3 Portal hypertension               1.4.4 Congenital heart diseases     
        1.4.5 Schistosomiasis                     1.4.6 Chronic hemolytic anemia   
   1.5 Persistent pulmonary hypertension of the newborn 
         Pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary  
         hemangiomatosis (PCH) 
2. Pulmonary hypertension owing to left heart disease 
    2.1 Systolic dysfunction    2.2 Diastolic dysfunction    2.3 Valvular disease 
3. Pulmonary hypertension owing to lung diseases and/or hypoxia 
    3.1 Chronic obstructive pulmonary disease    3.2 Ínterstitial lung disease 
    3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern 
    3.4 Sleep-disordered breathing                       3.5 Alveolar hypoventilation disorders 
    3.6 Chronic exposure to high altitude             3.7 Developmental abnormalities 
4. Chronic thromboembolic pulmonary hypertension (CTEPH) 
5. Pulmonary hypertension with unclear multifactorial mechanisms 
    5.1 Hematologic disorders: myeloproliferative disorders, splenectomy 
    5.2 Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis:  
          lymphangioleiomyomatosis, neurofibromatosis, vasculitis 
    5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders 
    5.4 Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure on dialysis 
 
Table 1: Updated Clinical Classification of Pulmonary Hypertension (Dana Point, 2008). 
PAH: pulmonary arterial hypertension; BMPR2: bone morphogenetic protein receptor type 2; 
ALK1: activin receptor-like kinase type 1; HIV: human immunodeficiency virus; PVOD: 
pulmonary veno-occlusive disease; PCH: pulmonary capillary hemangiomatosis; CTEPH: 
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chronic thromboembolic pulmonary hypertension. From Simonneau et al. J. Am. Coll. 
Cardiol. 2009; 54:S43-S54.  
 
Class I Patients with pulmonary hypertension but without resulting limitation of physical 
activity. Ordinary physical activity does not cause dyspnea or fatigue, chest pain or near 
syncope.                                                                                                                                  
Class II Patients with pulmonary hypertension resulting in a marked limitation of physical 
activity. They are comfortable at rest. Ordinary physical activity causes dyspnea or fatigue, 
chest pain or near syncope. 
Class III Patients with pulmonary hypertension resulting in marked limitation of physical     
activity. They are comfortable at rest. Less than ordinary activity causes dyspnea or fatigue, 
chest pain or near syncope. 
Class IV Patients with pulmonary hypertension. They are unable to carry out any physical 
activity without symptoms. These patients manifest signs of right heart failure. Dyspnea 
and/or fatigue may even be present at rest. Discomfort is increased by any physical activity. 
 
Table 2: Functional Assessment of Patients with Pulmonary Hypertension. From Rich et al. 
Executive summary from the second World Symposium on Primary Pulmonary Hypertension, 
Evian, France, September 6–10, 1998: World Health Organization.              
 
1.2.3 Epidemiology          
IPAH has an estimated incidence of 1 to 2 cases per 1 million population 44. It is 2 to 3 times 
more frequent in women than in men 45, 46 presenting most commonly in the third decade of 
life in women and in the fourth decade in men. Most cases of IPAH are sporadic; however, 
heritable PAH occurs in about 6% to 12% of patients with IPAH 47, 48. Heritable PAH is 
inherited in an autosomal dominant fashion, with incomplete penetrance (as low as 10% to 
20%) 45. Thus, most individuals who inherit the mutation have an estimated risk of 
approximately 10% of developing the disease 49.  
 
1.2.4 Clinical symptoms            
PAH may be asymptomatic in its early stages. The most common symptoms are exertional 
dyspnea, fatigue, and syncope and reflect an inability to increase cardiac output during 
activity. A small percentage of patients may report typical angina pectoris. The symptoms of 
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PAH can also include weakness and abdominal distension 44. Hemoptysis resulting from the 
rupture of distended pulmonary vessels is a rare but potentially devastating event. Raynaud’s 
phenomenon occurs in approximately 2% of patients with PAH. 
 
1.2.5 Physical signs                 
Physical signs of PAH become more apparent with the progression of right ventricular 
dysfunction. The presence of an accentuated pulmonary component of the second heart sound 
is very common, occurring in 90% of patients with IPAH. Other signs include (1) a right-
sided gallop, (2) a palpable right ventricular lift, (3) a mid-systolic ejection murmur across the 
pulmonary valve, (4) increased jugular venous pressure, (5) tricuspid regurgitation, (6) 
hepatomegaly and ascites, and (7) peripheral edema. Cyanosis may also indicate the presence 
of right-to-left shunting, severely decreased cardiac output or impairment in intrapulmonary 
gas transfer. 
 
1.2.6 Pathogenesis     
The pathogenesis of PAH is a complex process. PAH was long held to be a sign of pulmonary 
vasoconstriction and proliferation of vascular smooth muscle cells; however, mounting 
evidence implicates dysfunction of the pulmonary vascular endothelium in the pathogenesis 
of this disease. Changes in the production of a variety of endothelial-derived vasoactive 
mediators appear to be very critical in the development of PAH. Among these are 
prostacyclin, endothelin-1, and nitric oxide (Fig. 1). The imbalance of these mediators and 
their role in HPV and PH will be described later in chapter 1.3 about the endothelium. 
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Figure 1: Consequences of pulmonary artery endothelial cell dysfunction on pulmonary 
artery smooth muscle cell tone and proliferation. NO: nitric oxide; cAMP: cyclic 3', 5'-
adenosine monophosphate; cGMP: cyclic 3', 5'-guanosine monophosphate; PDE5: 
phosphodiesterase type 5; ET: endothelin; ETA: endothelin A receptor; ETB: endothelin B 
receptor. From Humbert et al. J. Am. Coll. Cardiol. 2004; 43: 13S-24S with modifications. 
 
1.2.7 Disease management        
 
1.2.7.1 General recommendations: 
- High altitude exposure should be avoided to prevent hypoxemia. 
- No smoking (nicotine is a vasoconstrictor). 
- Excessive sodium intake should be avoided to prevent salt retention. 
- Avoid hard physical activity. 
- Avoid hot baths or showers to prevent peripheral vasodilatation. 
- Need for supplemental oxygen during air travel. 
- All vasoconstrictor medications, appetite and diet pills should be avoided.  
 
                                                                                                                        INTRODUCTION 
 12 
1.2.7.2 Medical treatment 
 
1.2.7.2.1 Pulmonary vasodilator therapies  
Food and Drug Administration (FDA) approved agents for the treatment of PAH only (group 
1, Table 1). Recent pharmacologic treatment for PAH include prostanoids, endothelin 
receptor antagonists, and phosphodiesterase (PDE) 5 inhibitors (Table 3) 50. 
Drug class Drug Dose, Route 
Epoprostenol 
 
Start 2 ng/kg/min, IV 
and titrate to clinical effect 
Treprostinil 
 
0.625 - 40 ng/kg/min, IV/SQ 
18 - 54 µg inhalations, QID 
Prostanoids 
Iloprost 2.5 - 5 µg nebulized inhaled solution to 
maximum of nine doses daily 
Bosentan 62.5 - 125 mg BID, oral Endothelin-1 receptor 
antagonists Ambrisentan 5 - 10 mg/day, oral 
Sildenafil 20 mg TID, oral Phosphodiesterase 
Inhibitors Tadalafil 40 mg/day, oral 
   
Table 3: FDA-approved medications for PAH. IV: intravenous; SQ: subcutaneous; QID: four 
times a day; BID: two times a day; TID: three times a day; ng: nanogram; µg: microgram; mg: 
milligram; min: minute; kg: kilogram. From Falk et al. Vasc. Health Risk Manag. 2010; 6: 
273-280 with modifications.       
 
- Prostanoids: Epoprostenol is the most important drug in the treatment of PAH. It remains 
the treatment of choice for advanced disease. This potent, short-acting vasodilator and 
inhibitor of platelet aggregation is produced by vascular endothelium. A continuous 
intravenous infusion of epoprostenol improved exercise capacity, quality of life, 
hemodynamics and long-term survival in patients with functional class III or IV (Table 2) 51. 
Treprostinil is a prostacyclin analogue with a half life of 3 hours (h), which is a major 
advantage over epoprostenol. It can be given subcutaneously or intravenously. Iloprost is 
another prostacyclin analogue with a half life of 20-25 min. It can be administered by 
inhalation.  
- Endothelin-1 receptor antagonists: Bosentan is a non-selective endothelin receptor 
antagonist. Its use in patients with PAH has been associated with an improvement in 
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hemodynamic parameters and a decreased risk of clinical worsening 52, 53. Sitaxsentan and 
Ambrisentan are new selective ETA receptor antagonists, but they cause hepatotoxicity (as 
Bosentan) as a main side effect. 
- Phosphodiesterase 5 inhibitors: Cyclic guanosine monophosphate (cGMP) augmentation 
by nitric oxide leads to pulmonary vasodilatation (see 1.3.1.3). cGMP is rapidly degraded by 
PDEs. Sildenafil is a potent inhibitor of PDE5, it augments the pulmonary vascular response 
to endogenous NO. Its clinical use in patients with PAH has been associated with 
improvements in function and hemodynamics 54-57. Therefore, sildenafil may be efficacious in 
the treatment of PAH with acceptable side effects which include headache, nasal congestion, 
and visual disturbance. Tadalafil is another PDE5 inhibitor used in treatment of PAH. It has a 
longer half life (17.5 h) when compared to sildenafil (4 h), thus allowing once-daily dosing. 
PDE5 inhibitors have recently become attractive as the first line of choice in the treatment of 
milder forms of PAH. 
 
1.2.7.2.2 Interventional and surgical therapies: Despite advancement in the medical 
treatment of PAH, prognosis is still poor and patients may stabilize only for few years 
followed by deterioration again. Therefore further therapy may be necessary.  
- Atrial septostomy/stenting or septectomy 
This involves the creation of right to left interatrial shunt in the catheter lab (atrial 
septostomy/stenting) or surgically (atrial septectomy) to decompress the right heart failure. 
The time of interventions is very important because these surgical treatments have high 
mortality and morbidity rates, if performed in patients who are severely ill on inotropic 
support in intensive care units 58. However, due to its bad prognosis, it is normally used as a 
rescue method when medical therapy is not available.    
- Lung transplantation 
Lung transplantation is the surgery to replace a person’s diseased lung with a healthy one 
from a deceased donor. Lung transplantation is an option in some patients that are not 
responsive to other medical managements. This procedure may be useful for people who have 
PAH caused by severe lung disease. Shortage of donors is the main limiting factor in this 
process. After lung transplantation, survival rates decrease by time. 
 
1.3 Endothelium     
The endothelium has semipermeable properties and regulates the transfer of small and large 
molecules. Endothelial cells are dynamic and have both metabolic and synthetic functions. 
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They exert significant autocrine, paracrine and endocrine actions and influence smooth 
muscle cells, platelets and peripheral leucocytes 59. 
 
1.3.1 Endothelium-derived factors and their role in HPV and PH  
Alveolar hypoxia may potentially activate vascular endothelial cells to elicit basic alterations 
in their local production of vasodilative and vasoconstrictive mediators. Imbalances of the 
following mediators in the pulmonary vasculature participate in the development of 
vasoconstriction and pulmonary hypertension 60.  
 
1.3.1.1 Endothelin (ET)                   
The vasoconstrictor ET is produced by endothelial cells, with marked effects on vascular tone. 
There are three types of ET, but vascular endothelial cells produce only ET-1 61. ET-1 is a 21-
amino acid peptide. ET-1 has been found in lung tissue and pulmonary endothelial cells 62 and 
pulmonary blood vessels possess ET-1 receptors 63. ET-1 is a potent vasoconstrictor peptide, 
and hypoxia has been demonstrated to increase ET-1 gene expression 64.  
ET-1 increases intracellular calcium through multiple mechanisms directed by binding to G 
protein coupled receptors. These receptors stimulate phospholipase C activity leading to two 
important intracellular signalling messengers, inositol triphosphate and diacylglycerol. 
Binding of inositol triphosphate to sarcoplasmic reticulum triggers calcium release into the 
cytoplasm: diacylglycerol along with calcium activates protein kinase C which 
phosphorylates specific target proteins important in contraction and proliferation. ET-1 exerts 
vasoconstrictor actions through stimulation of ETA receptors in vascular smooth muscle and 
vasodilator actions through stimulation of ETB receptors in endothelial cells 65, 66. There is 
strong evidence that endothelium-derived ET-1 is a major player in the 
vasodilator/vasoconstrictor imbalance characteristic of PAH. Levels of lung and circulating 
ET-1 are increased in animals and patients with pulmonary hypertension of various etiologies 
67
. ET-1 may participate in HPV in isolated lung preparations, because HPV was markedly 
attenuated by either selective ETA or nonselective ET receptor antagonists 68, 69. Thus, HPV 
may be intrinsic for the SMC, but requires ET-1 for the full in vivo expression of the hypoxic 
vascular response. The basal level of endogenous ET-1 might amplify the depolarizing effect 
of hypoxia in vivo 70, 71. In chronic hypoxic rats ET-1 fulfills the priming role by sensitising 
the contractile apparatus through stimulation of Rho-kinase. The permissive role of ET-1 in 
HPV may also be played through suppression of KATP-channels 72.  
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1.3.1.2 Prostacyclin     
Prostacyclin was described as endothelium-derived relaxing factor in 1979. Prostacyclin binds 
to a G protein coupled receptor, thereby increasing concentration of cyclic adenosine 
monophosphate (cAMP) that activates protein kinase A and lowers intracellular calcium 
concentration. The effect of prostacyclin is also connected to NO effects. It facilitates NO 
release from endothelial cells and in turn NO potentiates prostacyclin effects in smooth 
muscle by inhibition of phosphodiesterases, which degrade cAMP 73. PH induced by chronic 
exposure to hypoxia can be inhibited in mice that overexpress the prostacyclin synthase gene 
74
. Furthermore, the comparative studies with wild-type (WT) mice and prostacyclin receptor 
knock-out mice showed that after exposure of the animals to chronic hypoxia, prostacyclin 
receptor knock-out mice developed a greater degree of pulmonary hypertension and 
pulmonary arterial media thickening than WT mice 75.  
 
1.3.1.3 Nitric oxide                              
NO is a relatively stable gas, with the ability to easily diffuse through the cell membrane. NO 
is one of the major endothelium-derived vasoactive mediators. It is synthesized from L-
arginine and oxygen by a family of three NO synthases (NOSs), all of which are expressed in 
the lung. Endothelial NOS (eNOS) appears to play an important role in maintaining low 
pulmonary vascular tone 76.    
NO stimulates soluble guanylyl cyclase (sGC) to synthesize cGMP that, in turn, activates 
cGMP-dependent protein kinase (PKG) which leads to the inhibition of calcium influx and 
decreased calcium calmodulin stimulation of myosin light chains. This, in turn, reduces the 
phosphorylation of myosin light chains, lowering smooth muscle tension, resulting in 
vasodilation 77. 
The actions of cGMP are limited via its catabolism by PDEs. In addition, NO can elicit effects 
via cGMP-independent mechanisms including interactions with heme-containing molecules 
(in addition to sGC) and proteins containing reactive thiol groups. NO plays an important role 
in many physiological processes and is important in regulation of the vascular system, 
neurotransmission and various homeostatic events 78. Synthesis of NO involves incorporation 
of molecular oxygen, and hypoxia might therefore be expected to reduce basal NO 
production. Hypoxia also can inhibit uptake of L-arginine, the NO precursor, by pulmonary 
arterial endothelial cells and may suppress the expression and the activity of NO synthase 79. 
It has been suggested, that this inhibition of NO production may be effectively causing HPV 
80
. However, although NO is the most important vasodilator that specifically suppresses HPV, 
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inhibition of NO synthase has no effect on normoxic tone and results in enhancement of HPV, 
findings which are thought to contradict the conclusion that reduced production of NO is the 
initiating mechanism of HPV 81, 82. With regard to chronic hypoxia, the vascular responses 
have partially been attributed to decreased concentration of NO 83. Chronic exposure to 
hypoxia reduces the production of both prostacyclin and NO, both substances that are 
antiproliferative 84. Thus, a reduction in their production could contribute to proliferation of 
SMC or fibroblasts. NO can induce reversible inactivation of the protein kinase C (PKC) 
pathway, an intracellular pathway associated with cell proliferation 79. 
 
1.3.1.3.1 Nitric oxide synthases 
Three isoforms of NOS characterized by different genes, different localization, regulation, 
catalytic properties and inhibitor sensitivity have been identified. These isoforms include 
nNOS (also known as Type I, NOS-I and NOS-1) predominating in neuronal tissue, iNOS 
(also known as Type II, NOS-II and NOS-2) which is inducible in a wide range of cells and 
tissues and eNOS (also known as Type III, NOS-III and NOS-3) being found in vascular 
endothelial cells. These isoforms have been also differentiated on the basis of their 
constitutive (eNOS and nNOS) versus inducible (iNOS) expression, and their calcium-
dependence (eNOS and nNOS) or -independence (iNOS). 
The most important isoform expressed in the pulmonary vasculature is eNOS. It was 
demonstrated in perfused lungs, that HPV in eNOS-deficient mice approximately doubled that 
in WT mouse lungs. However, there was a slight increase in HPV in iNOS-deficient lungs, 
and HPV in nNOS-deficient lungs was equal to that observed in WT mice. Therefore, in 
isolated perfused lungs eNOS is the main source of the NO that modulates the responses to 
hypoxia 76. The expression of all three isoforms has been reported to be increased 85, 86, 
whereas in another study only the levels of eNOS protein were increased in rats with hypoxic 
pulmonary hypertension 87. 
 
1.3.1.3.1.1 NOS inhibitors  
- Nω-Nitro-L-arginine (L-NNA) is an L-arginine analogue which causes inhibition of NO 
biosynthesis in vitro and in vivo. L-NNA increases arterial pressure in rats 88. In addition, L-
NNA causes coronary vasoconstriction, especially of the large coronary arteries 89. L-NNA 
elevated both pulmonary and systemic vascular tone during hypoxia 90. Several reports have 
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shown that administration of L-NNA to isolated lungs causes a marked vasoconstriction in 
rats with chronic hypoxic pulmonary hypertension 91, 92.  
 
- Methylarginine compounds are the most important endogenous NOS inhibitors. The 
methylation of protein arginine residues is catalyzed by a family of intracellular enzymes 
termed protein arginine methyltransferases (PRMTs). In mammalian cells, these enzymes 
have been classified into type I and type II, depending on their specific catalytic activity. Both 
types of PRMTs catalyze the formation of mono-methylarginine (MMA) from L-arginine. In 
the second step, type I PRMT form asymmetric ω- NG, NG-dimethylarginine (ADMA). 
However, type II PRMT produce symmetric ω- NG, N'G-dimethylarginine (SDMA) (Fig. 2) 93.  
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Figure 2: Synthesis of methylarginine compounds. SAM: S-adenosylmethionine; SAH: S-
adenosylhomocysteine; PRMT: protein arginine methyltransferases. From Bedford et al. Mol. 
Cell 2005; 18: 263-272 with modifications. 
 
After proteolytic degradation of methylated intracellular proteins, free MMA, SDMA, or 
ADMA can be released from cells. Released ADMA can be taken up by other cells via the 
cationic amino acid (y+) transporters, which are widely expressed in mammalian cells 94.  
ADMA has been detected in urine, plasma, cerebrospinal and broncho-alveolar lavage fluid 
(BALF), and various types of tissues 95. Free methylarginines are cleared from the body by 
renal excretion and hepatic metabolism. ADMA may control pulmonary cell functions 
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through inhibition of NOS and subsequently altered NO generation. Furthermore, the lung 
generates a significant amount of ADMA which may contribute to interstitial and plasma 
ADMA levels 96. The activity of the NOS enzymes can be competitively inhibited by L-
NMMA and ADMA. Both of these inhibitors are naturally occurring, but the concentration of 
ADMA in the human circulation is approximately 10 times greater than that of L-NMMA. In 
contrast, SDMA does not directly inhibit NOS function but is a potent inhibitor of the y+ 
transporter that mediates the intracellular uptake of arginine 94. In addition, elevated plasma 
ADMA concentrations are associated with multiple pathological conditions, including renal 
failure 97, hypertension 98, and hypercholesterolemia 99. Furthermore, some studies 
demonstrated that plasma ADMA concentrations are increased in patients with severe 
pulmonary hypertension 100 suggesting that NOS inhibition by ADMA may contribute to the 
disease. It was demonstrated that chronic hypoxia-induced PH is associated with increased 
levels of pulmonary concentrations of ADMA 101.    
 
1.3.1.3.2 Dimethylarginine dimethylaminohydrolase (DDAH) 
There are two DDAH isoforms, DDAH1 and DDAH2 102. Both of them are responsible for 
degradation of MMA and ADMA to citrulline and mono- or dimethylamines, respectively. 
DDAH activity controls endogenous ADMA concentrations and thus NOS activity. It was 
reported that the distribution of DDAH1 is similar to neuronal NOS, whereas the distribution 
of DDAH2 is similar to endothelial NOS, suggesting that DDAH1 and DDAH2 are expressed 
mainly in neuronal tissue and vascular endothelium, respectively 103. However, some studies 
reported that DDAH1 is highly expressed in vascular endothelial cells in hearts 104, which is 
consistent with another report showing strong DDAH1 expression in renal vascular 
endothelial cells 105. In transgenic mice with DDAH1 overexpression, ADMA levels should 
be reduced leading to increased NOS activity and consequently increased NO production and 
pulmonary vasodilation. It was reported, that the activity of DDAH enzyme in the lungs was 
decreased in chronic hypoxia-induced PH. This might be at least a result of the corresponding 
decrease in the protein expression of the DDAH1 isoform. Hypoxic exposure inhibits the 
expression of the DDAH1 isoform, thus increasing ADMA levels 101. 
 
1.3.1.3.3 Guanylate cyclases 
It was established in 1970 that guanylyl cyclase activity was found in both soluble (sGC) and 
particulate (pGC) fractions of most cells. sGC is a heterodimer composed of α1β1 and α2β2- 
isoforms, and is able to synthesize cGMP from GTP. The α1β1 is thought to be the 
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predominant heterodimer in the vasculature responsible for smooth muscle relaxation 106.  
However, the α2β2 heterodimer is prominent in synaptic membranes and may play a role in 
synaptic transmission 107. sGC is expressed in the cytoplasm of almost all mammalian cells 
and mediates a variety of important physiological functions, such as inhibition of platelet 
aggregation, relaxation of smooth muscle, vasodilatation, neuronal signal transduction, and 
immunomodulation 108. It was reported, that sGC-α1 is essential for the pulmonary vasodilator 
response to inhaled NO during HPV and limits pulmonary vascular remodeling and RV 
hypertrophy associated with chronic hypoxia-induced pulmonary hypertension 109. 
Metabolism of H2O2 leads to activation of guanylate cyclase and increased production of 
cGMP and vasodilatation. There is evidence that suggests that hypoxia may reduce H2O2-
stimulated production of cGMP in PASMCs. According to this hypothesis, hypoxia might 
decrease H2O2 production and subsequently decrease guanylate cyclase/cGMP induced 
pulmonary vasodilatation 110. It is also possible that hypoxia increases H2O2 level which 
oxidizes sGC and decrease cGMP. Some compounds like Bay41-2272 stimulate sGC and 
therefore can be used as systemic pulmonary vasodilator 111. It was also demonstrated that 
Bay41-2272, the sGC stimulator, and Bay58-2667, the sGC activator, reverse pulmonary 
hypertension in chronically hypoxic mice. Thus, sGC is considered an effective vasodilator in 
the treatment of hypoxia-induced pulmonary vascular diseases 112. In contrast, sGC is 
inhibited by 1H-[1, 2, 4]oxadiazolo[4, 3-a]quinoxalin-1-one (ODQ) which causes oxidation of 
the prothetic heme group of sGC, markedly reducing or inhibiting the pulmonary vasodilator 
effect of NO. ODQ has been used to examine the specificity of sGC activation induced by NO 
donors such as nitroglycerin 113.   
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2. AIM OF THE STUDY 
 
Hypoxia has long been known to elicit pulmonary vasoconstriction and pulmonary 
hypertension, but the mechanisms of hypoxic pulmonary vasoconstriction and hypoxia- 
induced pulmonary hypertension are still unclear. It has been proposed, that the endothelium 
plays an important role in the regulation of acute, and in particular sustained and chronic 
effects of hypoxia on pulmonary vasculature. Therefore, the aim of the current study was to 
investigate the role of dimethylarginine dimethylaminohydrolase 1 (DDAH-1), expressed in 
the endothelium, on the effects of acute, sustained and chronic hypoxia on pulmonary 
vasculature. NO is the most effective pulmonary vasodilator and is well known to influence 
hypoxia-induced alterations of lung vessels. It is synthesized from L-arginine by NO 
synthases which are strongly inhibited by ADMA, which is degraded by DDAH.  
Therefore this study aimed to: 
 
1- a) Compare the effect of acute and sustained hypoxia on PAP of isolated lungs of  
          DDAH1tg and WT mice.   
b) Elucidate the mechanism of DDAH1 induced effects on pulmonary vasculature. 
2- Compare the development of PH in DDAH1tg and WT mice exposed to 3 weeks of           
       chronic hypoxia by a) measurement of right ventricular systolic pressure, b)    
       morphometrical analysis and c) determination of right/left heart ratio.        
 
  
 
 
 
 
 
 
                                                                                                                                MATERIALS      
  
                                                                                                                                                                           21
3. MATERIALS 
 
3.1 Chemicals, solutions and drugs  
• Anti foam 204, Sigma-Aldrich, Steinheim, Germany 
• Aqua B.Braun Ecotainer®, Braun, Melsungen, Germany 
• Chlorhydric acid 1N, Merck, Darmstadt, Germany    
• 1H-[1, 2, 4]oxadiazolo[4, 3-a]quinoxalin-1-one, Sigma-Aldrich, Steinheim, Germany 
• Heparin Liquemin N 25000®, Roche, Basel, Swiss 
• Ketamine hydrochloride 100 mg/ml, Pfizer Pharma GmbH, Karlsruhe, Germany 
• Krebs-Henseleit electrolyte solution, Serag-Wiessner KG, Naila, Germany 
• Nω-Nitro-L-arginine, Sigma-Aldrich, Steinheim, Germany 
• Oncotic agent HAES®,  Fresenius Kabi, Bad Homburg, Germany  
• Potassium chloride, Fluka Biochemika, Buchs, Switzerland 
• Potassium dihydrogen phosphate, Merk, Darmstadt, Germany 
• Rompun 2% (xylazine hydrochloride), Bayer, Leverkusen, Germany 
• Sodium bicarbonate 8.4%, Serag-Wiessner KG, Naila, Germany 
• Sodium chloride, Fluka Biochemika, Buchs, Switzerland 
• Sodium hydroxide 1N, Merck, Darmstadt, Germany 
• Sodium nitrite, Sigma-Aldrich, Steinheim, Germany 
• Sterile isotonic saline solution (0.9% NaCl), Braun, Melsungen, Germany 
• UltraPure® DNase/RNase-Free Distilled Water, Invitrogen, Karlsruhe, Germany 
• Vanadium chloride, Sigma-Aldrich, Steinheim, Germany 
•  Composition of Krebs-Henseleit solution 
Sodium chloride 120 mM 
Potassium chloride 4.3 mM 
Potassium dihydrogen phosphate 1.1 mM 
Calcium chloride-dihydrate 2.4 mM 
Magnesium chloride-hexahydrate 1.3 mM 
Glucose 13.32 mM 
Hydroxyethylamylopectin (molecular weight 200.000): 5% (wt/vol.) 
 
Krebs-Henseleit electrolyte solution was used as a perfusion buffer. 24 mM of sodium 
bicarbonate was added to the perfusion buffer in order to adjust pH at 7.35 - 7.45. 
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3.2 Consumables 
• BD Microlance needles 21G and 26G, Becton Dickinson, Heidelberg, Germany 
• Cannula for left heart catheterisation support 22G and 20G, Braun, Melsungen, 
Germany  
• Cannula for pulmonary artery catheterisation support 22G and 20G, Braun, 
Melsungen, Germany  
• Combi-Stopper, Intermedica GmbH, Klein-Winternheim, Mainz, Germany 
• Combitips Plus 1 and 10 ml, Eppendorf Biopur®, Eppendorf AG, Hamburg, Germany  
• Combitrans Monitoring-Set, Braun, Melsungen, Germany 
• Disposable feather scalpel, Feather Safety Razor Company, Osaka, Japan 
• Disposable micropipettes intraMARK 50 µl, Blaubrand Brand GmbH, Wertheim-
Bettingen, Germany 
• Filter papers, Whatman Schleicher & Schuell GmbH, Dassel, Germany  
• Gauze balls size 6, Fuhrman Verbandstoffe GmbH, Munich, Germany 
• Hematocrit sealing compound, Blaubrand Brand GmbH, Wertheim-Bettingen, 
Germany 
• Heparinized microcapillary tubes, Hämacont, Heilbronn, Germany 
• Napkins, Tork, Mannheim, Germany 
• Pipette 10, 100  and 1000 µl, Eppendorf AG, Hamburg, Germany  
• Pipette tips, blue, yellow and white, Eppendorf AG, Hamburg, Germany 
• Single use gloves Transaflex®, Ansell, Surbiton Surrey, UK 
• Single use syringes Inject Luer® 1, 10 and 20 ml, Braun, Melsungen, Germany 
• Sterile gauze 5 x 4 cm Purzellin®, Lohmann und Rauscher, Rengsdorf, Germany 
• Surgical instruments, Martin Medizintechnik, Tuttlingen, Germany 
• Surgical threads non-absorbable ETHIBOND EXCEL® size 5-0, Ethicon GmbH, 
Norderstedt, Germany 
• Threads Nr. 12, Coats GmbH, Kenzingen, Germany 
• Tracheal cannula from BD Microlance 15 or 20G shortened to 1.5 cm, Becton 
Dickinson, Heidelberg, Germany 
• Tygon® lab tubing 3603, Cole-Parmer Instruments Company, Vernon Hills, Illinois, 
USA 
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3.3 Set-up for animal experiments  
• Blood analyser ABL 330, Radiometer, Copenhagen, Denmark 
• Frigomix1495, Braun, Melsungen, Germany 
• Magnetic stirrer Ret-Basic, IKA  Labortechnik, Staufen, Germany  
• Microliter centrifuge cooled Mikro 200R, Andreas Hettich GmbH & Co KG, 
Tuttlingen, Germany 
• Microliter centrifuge cooled Mikro 210, Andreas Hettich GmbH & Co KG, 
Tuttlingen, Germany 
• Microplate Reader ELx 808IU,  BIO-TEK® Instruments, Inc. Winooski, Vermont, 
USA 
• Microplate Washer, SLT-Lab Instruments, Achterwehr, Germany 
• Nitric Oxide Analyzer (NOA) Sievers 280, Foehr Medical Instruments (FMI) GmbH, 
Seeheim, Germany 
• Peristaltic pump REGLO Digital MS-4/12, Ismatech Labortechnik-Analytik, 
Glattbrugg, Switzerland  
• Piston pump Minivent Type 845, Hugo Sachs Elektronik Harvard Apparatus GmbH, 
March-Hugstetten, Germany 
• Research Grade Isometric Force Transducer, Harvard Apparatus, Holliston, USA 
• Shaker, Keutz Labortechnik, Reiskirchen, Germany   
• Thermomix UB, Braun, Melsungen, Germany 
• Transbridge BM4, World Precision Instruments, Berlin, Germany 
• Vortexer MS1 Minishaker, IKA  Labortechnik, Staufen, Germany 
 
3.4 Software 
• Data Acquisition Software LABTECH NOTEBOOK version 10.1, LABTECH, 
Andover, USA  
• NoaWin 32 Software, DeMeTec (development of measurement and medical 
technologies), Langgöns, Germany 
 
3.5 Materials for histology 
• Acetone, Sigma-Aldrich, Steinheim, Germany 
• 100 ml Automated microtom RM 2165,  Leica Microsystems, Nussloch, Germany 
• Biotin-Blocking kit, Vector/Linaris, Wertheim-Bettingen, Germany 
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• Cooling plate EG 1150C, Leica Microsystems, Nussloch, Germany  
• 3, 3'- Diaminobenzidine (DAB) substrat kit, Vector/Linaris, Wertheim-Bettingen, 
Germany 
• Disodium hydrogen phosphat-dihydrat pro analysis, Merck, Darmstadt, Germany 
• Digital Camera Microscope DC 300F, Leica Microsystems, Nussloch, Germany 
• Ethanol 70%, 96% and 99.6%, Fischer, Saarbrücken, Germany  
• Flattening bath for paraffin sections HI 1210, Leica Microsystems, Nussloch, 
Germany  
• Flattening table HI 1220, Leica Microsystems, Nussloch, Germany  
• Formaldehyde alcohol free 37%, Fischer, Saarbrücken, Germany  
• Histological glass slides Superfrost Plus®, R. Langenbrinck, Emmendingen, Germany 
• Horseradish peroxidase streptavidin, Alexis Biochemicals, Grünberg, Germany  
• Hydrogen peroxide 30% pro analysis, Merck, Darmstadt, Germany  
• Isopropanol 99.8%, Sigma-Aldrich, Steinheim, Germany 
• Laser capture micro dissection, Leica Microsystems, Nussloch, Germany 
• Methanol reinst, Sigma-Aldrich, Steinheim, Germany 
• Methyl green counter stain, Vector/Linaris, Wertheim-Bettingen, Germany  
• Microtom blades S35, Feather Safety Razor Company, Osaka, Japan 
• Mounting medium Pertex®, Medite GmbH, Burgdorf, Germany 
• Normal Horse Serum, Alexis Biochemicals, Grünberg, Germany 
• Parafilm, American National Can Menasha, Wisconsin, USA  
• Paraffin embedding medium Paraplast Plus®, Sigma-Aldrich, Steinheim, Germany  
• Pikric acid, Fluka Biochemika, Buchs, Switzerland 
• Potassium dihydrogen phosphat pro analysis, Merck, Darmstadt, Germany  
• Silicon, Sigma-Aldrich, Steinheim, Germany 
• Sodium chloride pro analysis, Fischer, Saarbrücken, Germany 
• Streptavidin blocking kit, Vector/Linaris, Wertheim-Bettingen, Germany 
• Stereo light microscope DMLA, Leica Microsystems, Nussloch, Germany 
• Tissue-embedding machine EG 1140H, Leica Microsystems, Nussloch, Germany  
• Tissue-processing automated machine TP 1050, Leica Microsystems, Nussloch, 
Germany  
• Trypsin Digest All 2®, Zytomed, Berlin, Germany  
• Universal-embedding cassettes, Leica Microsystems, Nussloch, Germany   
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• Vector VIP Substrat Kit, Vector/Linaris, Wertheim-Bettingen, Germany  
• Xylol, Fischer, Saarbrücken, Germany 
 
3.6 Antibodies   
• Anti-alpha-smooth muscle actin, Sigma-Aldrich, Steinheim, Germany  
• Anti-von Willebrand factor, Dako Cytomation, Hamburg, Germany  
• Secondary antibody (anti rabbit IgG antibody peroxidase-conjugated), Vector/Linaris, 
Wertheim-Bettingen, Germany 
 
3.7 System and software for morphometry 
• Computer Q 550 IW, Leica Microsystems, Nussloch, Germany  
• Software Qwin V3, Leica Microsystems, Nussloch, Germany  
• Macro for degree of muscularization, Leica Microsystems, Nussloch, Germany 
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4. METHODS 
 
4.1 Animals  
Adult WT mice (C57BL/6J) were purchased from Charles River (Sulzfeld, Germany). 
DDAH1 overexpressing mice were provided by John Cooke (Stanford University School of 
Medicine, Stanford, CA, USA). Animals had access to food and water ad libidum. All mice 
used in all experiments were 8 to 12 weeks of age, and weighed 20 to 28 g each. Animals 
were kept under pathogen free conditions and handled in accordance with the European 
Community recommendations for experimentation. All animal experiments were approved by 
the local authorities (Regierungspräsidium Giessen).  
 
4.2 Acute and sustained (3 h) hypoxic experiments 
 
4.2.1 Isolated, ventilated and perfused mouse lungs 
Isolated, perfused and ventilated mouse lungs have long been used by investigators interested 
in the physiological, biochemical, pharmacological and metabolic aspects of this complex 
organ 114. This technique has also been adapted to study the effects of different substances and 
drugs and the expected mechanisms by which they act. In addition, cells in the isolated 
perfused mouse lung are maintained in their “normal” anatomical and physiological 
associations and local physiological regulations in the organ. We took advantage of isolated 
mouse lungs as this model allows: 
1- Use of different genetically altered animals in order to identify the role of specific genes in 
our measurements. 
2- Use of several drugs to determine the dose and also to investigate the mechanism(s) by 
which they act.  
 
4.2.2 Isolation, perfusion and ventilation of mouse lungs 
In all experiments, lungs were totally separated from the remainder of the body. Mice were 
deeply anesthetized intraperitoneally with pentobarbital sodium (100 mg/kg body weight) and 
anticoagulated with heparin (1000 U/kg body weight) by intravenous injection. A median 
incision was done ventrally in the center of the neck, and the trachea was exposed by blunt 
dissection and partially transsected. Animals were then intubated via a tracheostoma and were 
ventilated with room air (tidal volume 250 µl; respiratory rate 90 breaths/min; positive end-
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expiratory pressure = 2 cm H2O) with a specific piston pump (Minivent Type 845, Hugo 
Sachs Elektronik Harvard Apparatus GmbH, March-Hugstetten, Germany). 
After midsternal thoracotomy the ribs were spread, the heart was incised at the apex and then 
the right ventricle was incised, and a fluid-filled perfusion catheter was immediately placed 
into the pulmonary artery and secured with a ligature. Immediately after insertion of the 
catheter, perfusion with a perfusion pump (REGLO Digital MS-4/12, Ismatech Labortechnik-
Analytik, Glattbrugg, Switzerland) with sterile Krebs-Henseleit solution (Serag-Wiessner KG, 
Naila, Germany) was started, the temperature of the system was 4°C at the beginning of the 
perfusion then gradually increased till 37.5°C. In parallel with the onset of artificial perfusion, 
ventilation was changed from room air to a pre-mixed normoxic normocapnic gas mixture 
with 21% O2, 5.3% CO2, balanced with N2 (Air Liquid, Deutschland GmbH, Ludwigshafen, 
Germany). 
Next, the trachea, lungs, and heart were excised en bloc from the thoracic cage without 
interruption of ventilation and perfusion and were freely suspended from a force transducer 
for monitoring of organ weight. A second perfusion catheter with cannula was introduced via 
the left ventricle into the left atrium (Fig. 3). Meanwhile, the flow was slowly increased from 
0.2 to 2 ml/min (total system volume 13 ml). After rinsing the lungs with more than 20 ml of 
buffer for washing the preparation from blood, the perfusion circuit was closed for 
recirculation. Left atrial pressure was fixed at 2.0 mmHg. The isolated, perfused lung was 
placed in a temperature-equilibrated housing chamber and the whole system (perfusate 
reservoirs, tubing, housing chambers) was heated to 37.5°C 115. 
For hypoxic ventilation, a gas mixture containing 1% O2, 5.3% CO2, balanced with N2 was 
used.
  
 
Figure 3: Isolated, perfused and ventilated mouse lung. 
 
About 30 min after the isolation of the lung, steady state period was achieved. When PAP 
values were stable for 15 min, the experiment was started. Pressures in the pulmonary artery, 
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the left ventricle and the trachea were registered by means of pressure transducers connected 
to the perfusion catheters via small diameter tubings and were digitised with an analogue-to-
digital converter, thus allowing data sampling with a personal computer (Fig. 4). The 
transducers were calibrated prior to each experiment. 
 
 
 
Figure 4: Schematic representation of the experimental set-up of the isolated, perfused and 
ventilated mouse lung. AMP: amplifier; BT: bubble trap; FT: force transducer; GN: normoxic 
gas supply; GH: hypoxic gas supply; IC: intraluminal catheter; LV: left ventricle; PA: 
pulmonary artery; PEEP: positive end-expiratory pressure; PT: pressure transducer; R: 
reservoir; RP: roller pump; REC: recording device; T: trachea; V: ventilator. From Seeger et 
al. Methods  Enzymol. 1994; 233:549-584 with modifications. 
 
In acute and sustained hypoxic experiments, after a normoxic ventilation (NOX) period for 15 
min, hypoxia (HOX) was applied for 10 min (acute phase), then changed to NOX for 15 min 
then to 3 h HOX (sustained phase) followed by 15 min NOX, another 10 min HOX and 
finally 10 min NOX.  
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4.2.3 Colorimetric determination of cGMP by Cayman’s cGMP-Kit (ELISA)  
The level of cGMP was measured by Cayman’s cGMP-Kit according to Cayman chemical 
company’s (Hamburg, Germany) instructions. 
1- Principle: Cayman’s cGMP assay is based on the competition between free cGMP in a 
sample (perfusate) and acetylcholinesterase (AChE) conjugated cGMP (cGMP tracer) for a 
limited amount of cGMP-specific rabbit antibody binding sites. The concentration of the 
cGMP tracer is held constant while the concentration of cGMP varies; the amount of cGMP 
tracer that is able to bind to the rabbit antibody is inversely proportional to the concentration 
of cGMP in the reaction well. This rabbit antibody-cGMP complex binds to the mouse 
monoclonal anti-rabbit immunoglobulin G (IgG) that has been previously attached to the well. 
The plate is washed to remove any unbound reagents and then Ellman’s reagent (which 
contains the substrate for AChE) is added to each well. 
The product of this enzymatic reaction has a distinct yellow color and absorbs light strongly at 
412 nm. The intensity of this color, determined spectrophotometrically, is proportional to the 
amount of cGMP tracer bound to the well, which is inversely proportional to the amount of 
free cGMP present in the well during the incubation. When the concentration of cGMP in the 
sample is very low, the sensitivity of the reaction can be increased by an acetylation 
procedure for both, the standard and the experimental samples, because antibody binding is 
increased, if an acetyl group is present on the 2-hydroxyl group of the cGMP. 
The concentration of cGMP was determined in samples of pulmonary venous effluent during 
different experimental time periods of the isolated lung experiments. Perfusate samples were 
taken from venous effluent during the experiment at the time points of 10, 20, 35, 45 and 220 
min (10 and 35 min were during normoxic ventilation, while the other time points were 
during hypoxic ventilation) and immediately frozen in liquid nitrogen and stored at –20°C  
until measurement. The materials provided by the company for performing the assay are listed 
in Table 4. 
Catalog number Item 96 wells, quantity/size 
481022 cGMP EIA antiserum 1 vial/100 dtn 
481020 cGMP AChE tracer 1 vial/100 dtn 
481024 cGMP EIA standard 1 vial 
400060 EIA buffer concentrate (10X) 2 vials/10 ml 
400062 Wash buffer concentrate 
(400X) 
1 vial/5 ml 
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400035 Tween 20 1 vial/3 ml 
400004 Mouse anti-rabbit IgG coated 
plate 
1 plate 
400012 96-Well cover sheet 1 cover 
400050 Ellman’s reagent 3 vials/100 dtn 
400031 Acetic anhydride 1 vial/2.5 ml 
400029 KOH 1 vial 
400040 EIA tracer dye 1 vial 
400042 EIA antiserum dye 1 vial 
 
2- Table 4: Materials supplied from Cayman Chemical Company for cGMP measurement. 
cGMP: cyclic 3', 5'-guanosine monophophate; EIA: enzyme immuno assay; dtn: determinant; 
AChE: acetylcholinesterase; IgG: immunoglobulin G; KOH: potassium hydroxide. 
 
3- Measurement was performed as follows:  
Acetylation procedure: To 500 µl of sample/standard, 100 µl of 4 M KOH and 25 µl acetic 
anhydride were added in quick succession, shaken for 15 seconds, then 25 µl of 4 M KOH 
was added and vortexed again for also 15 seconds. This was repeated for all samples and 
standard tubes. 
Addition of the reagents 
The scheme of the plate set-up is given in Table 5. 
 1- 100 and 50 µl enzyme immuno assay (EIA) buffer were added to non-specific binding 
(NSB) and maximum binding (Bo) wells, respectively. 
 2- 50 µl from standard/sample were added to their specific wells in a duplicate.  
 3- 50 µl from cGMP AChE tracer was added to each well except the total activity (TA) and 
the blank (Blk) wells. 
 4- 50 µl from cGMP EIA antiserum was added to each well except TA, NSB and Blk wells. 
Then the plate was covered with plastic film, and was incubated for 18 hours at room 
temperature. 
Development of the plate 
 1- Ellman’s reagent was reconstituted immediately before use with 20 ml UltraPure water. 
 2- Solutions in the wells were discarded and the wells were rinsed five times with wash   
buffer. 
 3- 200 µl of Ellman’s reagent was added to each well. 
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 4- 5 µl of tracer was added to TA well. 
 5- The plate was covered with plastic film. Optimum development was obtained by using an         
orbital shaker for 90 min at 4°C. 
Reading the plate  
 1- The bottom of the plate was wiped with clean tissue to remove fingerprint, dirt etc. 
 2- The plate cover was removed carefully. 
 3- The plate was read at a wavelength between 405 and 420 nm by using ELx 808IU (BIO-
TEK® Instruments, Inc. Winooski, Vermont, USA) connected to a computer which contained 
software to calculate the concentrations automatically. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A Blk Blk S1 S1 1 1 9 9 17 17 25 25 
B Blk Blk S2 S2 2 2 10 10 18 18 26 26 
C NSB NSB S3 S3 3 3 11 11 19 19 27 27 
D NSB NSB S4 S4 4 4 12 12 20 20 28 28 
E Bo Bo S5 S5 5 5 13 13 21 21 29 29 
F Bo Bo S6 S6 6 6 14 14 22 22 30 30 
G Bo Bo S7 S7 7 7 15 15 23 23 31 31 
H TA TA S8 S8 8 8 16 16 24 24 32 32 
 
Table 5: Sample plate format for cGMP measurement. Blk: blank; NSB: non-specific 
binding; Bo: maximum binding; TA: total activity; S1-S8: standard 1-8; 1-32: samples.  
 
4- Definitions: 
1- Blank: Background absorbance caused by Ellman’s reagent. 
2- Total activity: Total enzyme activity of AChE-linked tracer. 
3- NSB (Non-Specific Binding): Non-immunological binding of the tracer to the well. Even 
in the absence of specific antibody a very small amount of tracer still binds to the well; the 
NSB is a measure of this low binding. 
4- Bo (maximum binding): Maximum amount of tracer that the antibody can bind in the 
absence of sample. 
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5- % B/Bo (% Bound/Maximum Bound): Ratio of the absorbance of a particular sample or 
standard well to that of the maximum binding well. 
6- Dtn: Determinant, one dtn is the amount of reagent used per well. 
 
4.2.4 Colorimetric determination of ADMA by using ADMA-Kit (ELISA) 
For determination of ADMA, the ADMA-Kit of DLD Diagnostika GmbH, Hamburg, 
Germany, was used. 
1- Principle: The competitive ADMA-ELISA assay uses the microtiter plate format. ADMA 
is bound to the solid phase of the microtiter plate. ADMA in a sample (perfusate) is acylated 
and competes with solid phase bound ADMA for a fixed number of rabbit anti-ADMA 
antiserum binding sites. When the system is in equilibrium, free antigen and free antigen-
antiserum complexes are removed by washing. The antibody bound to the solid phase ADMA 
is detected by anti-rabbit IgG conjugated with peroxidase. The amount of antibody bound to 
solid phase ADMA is inversely proportional to the ADMA concentration of the sample. The 
substrate tetramethylbenzidine (TMB)/peroxidase reaction is monitored at 450 nm. Perfusate 
samples were taken from venous effluent during the experiment at the time points of 10, 20, 
35, 45 and 220 min (10 and 35 min were during normoxic ventilation, while the other time 
points were during hypoxic ventilation) and immediately frozen in liquid nitrogen and stored 
at –20°C until measurement. The materials provided by the company for performing the assay 
are listed in Table 6. 
Microtiter-Strips: 8 wells each, break apart precoated with ADMA 12 strips 
Standards 1 – 6: in a concentration of 0.0, 0.1, 0.3, 0.6, 1.0, 5.0 µmol/l,  each 
4 ml, ready for use 
6 vials 
Control 1 & 2: each 4 ml, ready for use 2 vials 
Acylation buffer: 3.5 ml, ready for use 1 bottle 
Acylation reagent: dissolve content in 2.8 ml solvent before use 2 vials 
Antiserum: 5.5 ml, ready for use, rabbit-anti-N-acyl-ADMA 1 vial 
Enzyme conjugate: 12 ml, ready for use, goat anti-rabbit-IgG-peroxidase 1 vial 
Wash buffer: 20 ml, concentrated, dilute content with distilled water to 500 
ml total volume, store at 2 - 8°C. 
1 bottle 
Substrate: 12 ml TMB solution, ready for use 1 vial 
Stop solution: 12 ml, ready for use, contains 0.3 M sulphuric acid 1 vial 
Reaction Plate: for acylation 1 piece 
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Equalizing reagent: dissolve content with 20.5 ml distilled water, dissolve 
carefully to minimize foam formation 
1 vial 
Solvent: 6 ml, contains acetone/DMSO 1 vial 
 
2- Table 6: Contents of the kit used in ADMA measurement. ADMA: asymmetric ω- NG, NG-
dimethylarginine; IgG: immunoglobulin G; TMB: tetramethylbenzidine; DMSO: dimethyl 
sulfoxide. 
 
3- Measurement was performed as follows: 
- Preparation of samples (acylation): The wells of the reaction plate for the acylation can be 
used only once. 
1- 20 µl standard 1 - 6, each 20 µl control 1 & 2 and each 20 µl samples were added into the 
respective wells of the reaction plate. 
2- 25 µl acylation buffer was added into all wells. 
3- 200 µl equalizing reagent was pipetted into all wells, mixing the reaction plate for 10 
seconds. 
4- 50 µl prepared acylation reagent was added to wells, mixed immediately, then the reaction 
plate was incubated for 90 min at room temperature (approx. 20°C) on an orbital shaker 
without covering the wells or the plate. Afterwards, all reagents were transferred to room 
temperature and mixed carefully. 
- Sample incubation: Each 50 µl prepared standards, 50 µl prepared controls and 50 µl 
prepared samples was added to the respective wells of the coated microtiter strips in a 
duplicate design, then 50 µl antiserum was pipetted into all wells and shaken shortly on an 
orbital shaker. The plate was covered with adhesive foil and incubated for 15 – 20 h at 4°C. 
- Washing: The solution contents of the wells were discarded and washed thoroughly with 
each 250 µl wash buffer (shaken shortly on an orbital shaker). This procedure was repeated 4 
times. Residual liquid was removed by tapping the inverted plate on clean absorbent paper. 
- Conjugate incubation & washing: Each 100 µl enzyme conjugate was added to each well, 
and then incubated for 60 min at room temperature on an orbital shaker, and then step 3 was 
repeated. 
- Substrate incubation: Each 100 µl substrate was added into all wells and incubated for 20 
to 30 min at room temperature on an orbital shaker. 
- Stopping: 100 µl stop solution was pipetted to each well. 
                                                                                                                                   METHODS 
 34 
- Reading: The optical density was determined at 450 nm by using a microplate photometer. 
The concentrations of the samples were calculated. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A S1 S1 1 1 9 9 17 17 25 25 33 33 
B S2 S2 2 2 10 10 18 18 26 26 34 34 
C S3 S3 3 3 11 11 19 19 27 27 35 35 
D S4 S4 4 4 12 12 20 20 28 28 36 36 
E S5 S5 5 5 13 13 21 21 29 29 37 37 
F S6 S6 6 6 14 14 22 22 30 30 38 38 
G C1 C1 7 7 15 15 23 23 31 31 39 39 
H C2 C2 8 8 16 16 24 24 32 32 40 40 
 
Table 7: Sample plate format for ADMA measurement. S1-S6: standard 1-6; C1, C2: control 
1 & 2; 1-40: samples  
 
4.2.5 Measurement of NO metabolites in perfusate  
The metabolic products of NO (nitrite, nitrate and peroxynitrite) were determined in perfusate 
samples by using Nitric Oxide Analyzer (NOA) “Sievers 280” (FMI GmbH, Seeheim, 
Germany) according to manufacturer instructions. Perfusate samples were taken from venous 
effluent during the experiment at the time points of 10, 20, 35, 45 and 220 min (10 and 35 min 
were during normoxic ventilation, while the other time points were during hypoxic 
ventilation) and immediately frozen in liquid nitrogen and stored at –20°C until measurement. 
The principle of NO measurement depends on the reduction of NO metabolic products by 
vanadium chloride in hydrochloric acid at 95°C (to achieve high conversion efficiency) to NO 
gas which is provided to the NO analyzer connected to a computer for data transfer and 
analysis by using “NoaWin 32” software (DeMeTec, Langgöns, Germany). If the samples 
contain high levels of protein, the reagent will start to foam as samples are injected. An 
antifoaming 204 agent (a mixture of non-silicone organic defoamers in a polyol dispersion) 
(100 µl) was therefore added to the purge vessel containing vanadium chloride solution at the 
beginning of the experiment. To prevent damage to the NOA from hydrochloric acid vapour, 
a gas bubbler filled with aqueous sodium hydroxide was installed between the purge vessel 
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and the NOA. A standard solution of 100 mM sodium nitrite was prepared and dilutions of the 
standard used for constructing the calibration curve. NO concentration can be determined 
from the peak which appears about 30 seconds after injection of the sample. All samples were 
measured in a duplicate. 
 
4.3 Chronic hypoxic experiments 
Pulmonary hypertension was induced in mice by exposure to hypoxia (10% inspired O2 
fraction) in a normobaric chamber for 21 days. Constant level of hypoxia was maintained with 
the aid of an autoregulatory control unit (model 4010, O2 controller, Labotec, Göttingen, 
Germany) supplying either nitrogen or oxygen. Excess humidity in the system was prevented 
by condensation in a cooling system. CO2 was continuously removed by soda lime. Cages 
were opened for food and water supply and for cleaning. The chamber temperature was 
maintained at 22-24°C. Control animals were placed in similar condition in a normoxic 
chamber with normal oxygen environment (21% inspired O2 fraction).  
 
4.3.1 In vivo hemodynamic measurements 
For general anesthesia, mice were given an intraperitoneal injection of a combination of 
ketamine and xylazine (100 mg/kg, and 15 mg/kg, body weight, respectively). The anesthetic 
mixture was prepared as a mixture of 20 µl ketamine, 20 µl xylazine and 40 µl NaCl, the 
required volume to achieve the specific dose was injected and mice were anticoagulated with 
heparin (1000 U/kg). The anesthetized animals were placed in a heating chamber in order to 
maintain the body temperature within the physiological range. The trachea was cannulated, 
and the lungs were ventilated with room air at a tidal volume of 200 µl and at a rate of 120 
breaths/min. A positive end expiratory pressure (PEEP) of 1.0 cm H2O was used throughout 
the experiment. Through a small opening in the chest a 26-gauge stainless steel needle 
attached to a filled force transducer was carefully inserted into the right ventricle to measure 
the right ventricular systolic pressure (RVSP). The transducer was calibrated before every 
measurement. RVSP was recorded for 20 min and the saved data was printed for analysis. 
After RVSP measurement, blood was collected directly from the right ventricle for hematocrit 
measurement. Hematocrit was measured immediately by capillary centrifugation technique. 
The capillary tube containing the whole blood was spun in an Adams Autocrit Centrifuge for 
5 min and hematocrit values were obtained.  
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4.3.2 Vascular morphometry 
After finishing hemodynamic measurements, an incision in left ventricle was made, mouse 
lungs were first flushed with sterile saline solution at a constant pressure of 22 cm H2O above 
the pulmonary artery via the pulmonary artery, in order to get rid of blood, and then fixed by 
passing phosphate-buffer paraformaldehyde through the pulmonary artery. Saline was infused 
through the trachea. For vascular morphometry, after 15-25 min, lungs were gently isolated 
from the chest cavity and allowed to immerse overnight in a fixative solution. Fixed lungs 
were transferred to 0.1 M PBS (phosphate-buffered saline) on the following day. Afterwards, 
the lung lobes were individually placed in histological cassettes and dehydrated in an 
automated dehydration station and then embedded in paraffin blocks. Staining was done on 3 
µm lung sections for vascular morphometry.  
The degree of muscularization in small pulmonary arteries was investigated in mouse lung 
paraffin sections after staining with the specific antibodies against α-actin (for smooth 
muscle) and vonWillebrand factor (vWf) (for endothelial cell). The detailed protocol is given 
in the following tabular form (Table 8). 
Incubation 
time (min) Reagent Remarks 
60 Heating slide with parrafin section  58οC 
30 
Xylol, fresh xylol was used every 
10 min    
10 
Ethanol 99.6%, after 5 min fresh 
ethanol 99.6% was used   
5 Ethanol 96%   
5 Ethanol 70%   
15 H2O2 - methanol mixture 3% 
180 ml methanol + 20 ml H2O2  30% 
(freshly prepared) 
10 
H2O, after 5 min fresh H2O was 
used 
  
10 
PBS, fresh PBS was used every 5 
min   
15 Trypsin (1 ml trypsin + 2 ml diluent) 
50 Incubation at 37οC  
15 PBS, fresh PBS was used every 5   
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min 
15 Streptavidin blocking   
5 PBS   
15 Biotin blocking   
5 PBS   
15 10% Bovine serum albumin (BSA)   
10 
PBS, fresh PBS was used every 5 
min   
60 
Mouse IgG blocking reagent, 
mouse on mouse (M.O.M.) 
(reagent 1)  
100 µl IgG blocking reagent + 2.5 
ml PBS 
15 
PBS, fresh PBS was used every 5 
min 
  
5 
M.O.M. diluent/protein blocking 
(reagent 2) 
7.5 ml PBS + 600 µl protein 
concentrate 
30 Primary antibody (α-actin) 1:900 dilution with 10% BSA 
20 
PBS, fresh PBS was used every 5 
min   
10 
M.O.M. biotinylated IgG reagent 
(reagent 3)  
10 µl reagent 3 + 2.5 ml M.O.M 
diluent 
20 
PBS, fresh PBS was used every 5 
min 
  
30 
Horseradish peroxidase 
streptavidin, R. T. U. (ready to 
use)  
15 
PBS, fresh PBS was used every 5 
min  
3 to 4 
Vector VIP (very intense purple) 
substrate kit 
5 ml PBS + 150 µl reagent 1 + 150 
µl reagent 2 + 150 µl reagent 3 + 
150 µl H2O2 solution then the 
intensity of the purple color was 
checked microscopically. 
5 H2O   
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10 
PBS, fresh PBS was used every 5 
min   
20 10% BSA   
15 
PBS, fresh PBS was used every 5 
min   
20 Serum block 1 2.5% normal horse serum 
30 
Primary antibody (vonWillebrand 
factor (vWF)) 1:900 dilution with 10% BSA 
20 
PBS, fresh PBS was used every 5 
min 
  
30 
Secondary antibody (anti rabbit 
IgG peroxidase)  
20 
PBS, fresh PBS was used every 5 
min   
1/2 
3, 3'- Diaminobenzidine (DAB) 
substrate kit 
5 ml aqua dest  + 100 µl buffer pH 
7.5 + 200 µl DAB substrate + 100 µl 
H2O2  
5 H2O   
3 Counter stain with methyl green  under 60οC in heating plate 
1 H2O   
2 Ethanol 96%   
10 
Isopropanol, after 5 min fresh 
isopropanol was used   
15 
Xylol, after 5 min fresh xylol was 
used 
  
Apply Cover slip fixation with pertex as gluing agent (glass covering) 
 
Table 8: Protocol for double antibody immunostaining against α-actin and vWF factor. H2O2 
hydrogen peroxide; PBS: phosphate-buffered saline; IgG: immunoglobulin G; BSA: Bovine 
serum albumin; DAB: 3, 3'- Diaminobenzidine; min: minute; µl: microliter; ml: milliliter; 
M.O.M.: mouse on mouse; vWf: vonWillebrand factor; R. T. U.: ready to use; VIP: very 
intense purple.
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Morphometric quantification was carried out microscopically using a Qwin macro program 
from Leica 116. This program automatically recognized α-actin stained color and categorized 
vessel into fully muscularized (> 70% vessel circumference), partially muscularized (5%-70% 
vessel circumference) and non-muscularized (< 5% vessel circumference). One hundred 
pulmonary arteries (80 vessels for 20-70 micrometer diameter vessels, 15 vessels for 70-150 
micrometer vessels and 5 vessels for more than 150 micrometer vessels) were analyzed from 
each lung lobe in a blinded fashion. The degree of muscularization is given as percentage of 
total vessel count. 
 
4.3.3 Heart ratio 
After RVSP and hematocrit measurements and after lung isolation from the chest cavity, all 
hearts from mice of the different groups were isolated and dissected under a dissection 
microscope. The right ventricle (RV) was separated from the left ventricle plus septum 
(LV+S). After separation, they were placed on glass slides and dried for 1 week at room 
temperature. The right to left ventricle plus septum weight ratio (RV/LV+S) was calculated, 
as an index of right ventricular hypertrophy. 
 
4.4 Statistical analysis 
All data are expressed as means ± SEM. Comparison of multiple groups was performed by 
analysis of variance (ANOVA) with the Student-Newman-Keuls post test. For comparison of 
two groups a Student’s t-test was performed. P value below 0.05 was considered as statistical 
significant for all analysis.  
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5. RESULTS 
 
To investigate the role of DDAH1 on the effects of acute, sustained and chronic hypoxia on 
pulmonary vasculature, mice overexpressing the enzyme DDAH1, which is responsible for 
degradation of ADMA, were employed. 
 
5.1 Acute and sustained hypoxic experiments 
Lungs were exposed to normoxic ventilation (21% O2) for 15 min, followed by a period of 10 
min exposure to hypoxia (1% O2) and then to normoxia again for 15 min. After that a 3 hour 
period of sustained hypoxic ventilation was applied, followed by normoxia for 15 min, and 
another acute hypoxic challenge (Fig. 5).  
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Figure 5: Representative recording of PAP, weight changes (referred to the start of the 
experiment after the steady state period) and LVP during acute and sustained hypoxia of 
isolated lungs of WT mice. PAP: pulmonary artery pressure; LVP: left ventricle pressure; 
NOX: normoxia; HOX: hypoxia; min: minute; g: gram. 
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5.1.1 PAP of isolated lungs of WT & DDAH1tg mice during acute and sustained hypoxic 
ventilation   
There were no differences in PAP during the first acute hypoxic ventilation period (lasting 10 
min) between WT and DDAH1tg mice. Also the kinetics of the response was the same. 
However, during sustained hypoxic ventilation (lasting 3 hours), there were differences in the 
strength of HPV between WT and DDAH1tg mice. Upon starting sustained hypoxic 
ventilation, PAP had the tendency to be decreased in DDAH1tg compared to WT mice. This 
decrease became statistically significant at min 125 and lasted till the end of the experiments 
(Fig. 6). 
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Figure 6: PAP of isolated lungs of WT and DDAH1tg mice during acute and sustained 
hypoxic ventilation. PAP of isolated lungs of DDAH1tg mice was significantly decreased at 
min 125 till end of the experiments. Data are expressed as mean ± SEM (n=9 for control 
group, n=10 for DDAH1tg group); PAP: pulmonary artery pressure; WT: wild-type; 
DDAH1tg: dimethylarginine dimethylaminohydrolase 1 overexpressed; min: minute; NOX: 
normoxia; HOX: hypoxia; *P<0.05 compared to WT mice. 
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5.1.2 PAP of isolated lungs of WT & DDAH1tg mice during normoxic ventilation 
The experiments revealed no significant differences in PAP between WT and DDAH1tg mice 
in the course of 255 min of normoxic ventilation (Fig. 7). 
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Figure 7: PAP of isolated lungs of WT and DDAH1tg mice during normoxic ventilation. Data 
are expressed as mean ± SEM (n=3 mice for each group); PAP: pulmonary artery pressure; 
WT: wild-type; DDAH1tg: dimethylarginine dimethylaminohydrolase 1 overexpressed; min: 
minute; NOX: normoxia. 
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5.1.3.1 Effect of L-NNA on pulmonary vasoconstriction induced by acute & sustained 
HOX in WT and DDAH1tg mice  
Administration of L-NNA in isolated lungs of WT mice 5 min before the first acute hypoxic 
ventilation maneuver at a dose of 400 µM resulted in a significant increase in PAP at the time 
period starting from min 55 to min 125 compared to the untreated WT mice (Fig. 8). 
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Figure 8: Effect of L-NNA on PAP of isolated lungs of WT mice. PAP was significantly 
increased from min 55 to min 125 in the L-NNA treated group compared to the control group. 
Data are expressed as mean ± SEM (n=9 for control group, n=7 for L-NNA group); PAP: 
pulmonary artery pressure; L-NNA: Nω-Nitro-L-arginine; WT: wild-type; min: minute; NOX: 
normoxia; HOX: hypoxia; *P<0.05 compared to control group. 
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Administration of L-NNA in isolated lungs of DDAH1tg mice 5 min before the first acute 
hypoxic ventilation maneuver at a dose of 400µM caused a significant elevation of PAP 
starting early after starting sustained hypoxic ventilation (min 50) till the end of experiments 
(Fig. 9). 
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Figure 9: Effect of L-NNA on PAP of isolated lungs of DDAH1tg mice. PAP was 
significantly increased from min 50 till the end of experiments in presence of L-NNA 
compared to the control group. Data are expressed as mean ± SEM (n=10 for control group, 
n=7 for L-NNA treated group); PAP: pulmonary artery pressure; L-NNA: Nω-Nitro-L-
arginine; DDAH1tg: dimethylarginine dimethylaminohydrolase 1 overexpressed; min: minute; 
NOX: normoxia; HOX: hypoxia; *P<0.05 compared to control group. 
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When comparing directly the effect of DDAH1 overexpression on HPV in DDAH1tg mice to 
WT mice in presence of L-NNA, it was found that PAP showed no significant differences in 
WT treated mice compared to DDAH1tg treated mice (Fig. 10). 
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Figure 10: Effect of L-NNA on PAP of isolated lungs of DDAH1tg mice compared to WT 
mice. Data are expressed as mean ± SEM (n=7 for each group); PAP: pulmonary artery 
pressure; L-NNA: Nω-Nitro-L-arginine; WT: wild-type; DDAH1tg: dimethylarginine 
dimethylaminohydrolase 1 overexpressed; min: minute; NOX: normoxia; HOX: hypoxia. 
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5.1.3.2 Effect of L-NNA on PAP of isolated lungs of WT & DDAH1tg mice during 
normoxic ventilation 
Administration of L-NNA in isolated lungs of WT and DDAH1tg mice 10 min after reaching 
steady state resulted in no significant difference of PAP in the course of 255 min of normoxic 
ventilation (Fig. 11) when comparing WT mice and WT mice + L-NNA (A), comparing 
DDAH1tg mice and DDAH1tg mice + L-NNA (B) and comparing WT mice + L-NNA and 
DDAH1tg mice + L-NNA (C).  
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Figure 11 A, B, C: Effect of L-NNA on PAP of isolated lungs of WT & DDAH1tg mice 
during normoxic ventilation. Data are expressed as mean ± SEM (n=3 for each group); PAP: 
pulmonary artery pressure; WT: wild-type; DDAH1tg: dimethylarginine 
dimethylaminohydrolase 1 overexpressed; L-NNA: Nω-Nitro-L-arginine; min: minute; NOX: 
normoxia; µM: micromolar. 
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5.1.4.1 Effect of ODQ on pulmonary vasoconstriction induced by acute & sustained 
HOX in WT and DDAH1tg mice 
Administration of ODQ in isolated lungs of WT mice 5 min before the first acute hypoxic 
ventilation at a dose of 10 µM caused a significant increase in PAP in the time period from 
min 165 to min 220 compared to the untreated WT mice (Fig. 12). 
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Figure 12: Effect of ODQ on PAP of isolated lungs of WT mice. PAP was significantly 
increased from min 165 to min 220 in the ODQ treated group compared to the control group.  
Data are expressed as mean ± SEM (n=9 for control group, n=6 for ODQ group); PAP: 
pulmonary artery pressure; WT: wild-type; ODQ: 1H-[1, 2, 4]oxadiazolo[4, 3-a]quinoxalin-1-
one; min: minute; NOX: normoxia; HOX: hypoxia; *P<0.05 compared to control group. 
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Administration of ODQ in isolated lungs of DDAH1tg mice 5 min before the first acute 
hypoxic ventilation at a dose of 10 µM caused a significant increase in PAP at the time period 
starting from min 55 till the end of experiments compared to the untreated control DDAH1tg 
mice (Fig. 13). 
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Figure 13: Effect of ODQ on PAP of isolated lungs of DDAH1tg mice. PAP was significantly 
increased from min 55 till the end of experiments in presence of ODQ compared to the 
control group. Data are expressed as mean ± SEM (n=10 for control group, n=5 for ODQ 
group); PAP: pulmonary artery pressure; DDAH1tg: dimethylarginine 
dimethylaminohydrolase 1 overexpressed; ODQ: 1H-[1, 2, 4]oxadiazolo[4, 3-a]quinoxalin-1-
one; min: minute; NOX: normoxia; HOX: hypoxia; *P<0.05 compared to control group. 
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When comparing directly the effect of DDAH1 overexpression on HPV in DDAH1tg mice to 
WT mice in presence of ODQ, it was found that PAP was significantly decreased in the time 
period from min 200 to min 220 in DDAH1tg treated mice compared to WT treated mice  (Fig. 
14).  
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Figure 14: Effect of ODQ on PAP of isolated lungs of DDAH1tg mice compared to WT mice. 
PAP was significantly decreased in the time period from min 200 to min 220 in DDAH1tg 
treated mice compared to WT treated mice. Data are expressed as mean ± SEM (n=6 for WT 
+ ODQ group, n=5 for DDAH1tg + ODQ group); PAP: pulmonary artery pressure; WT: wild-
type; DDAH1tg: dimethylarginine dimethylaminohydrolase 1 overexpressed; ODQ: 1H-[1, 2, 
4]oxadiazolo[4, 3-a]quinoxalin-1-one; min: minute NOX: normoxia; HOX: hypoxia; *P<0.05 
compared to WT treated mice. 
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5.1.4.2 Effect of ODQ on PAP of isolated lungs of WT & DDAH1tg mice during 
normoxic ventilation 
Administration of ODQ in isolated lungs of WT and DDAH1tg mice 10 min after reaching 
steady state resulted in no significant difference in PAP in the course of 255 min of normoxic 
ventilation (Fig. 15) when comparing WT mice and WT mice + ODQ (A), comparing 
DDAH1tg mice and DDAH1tg mice + ODQ (B) and comparing WT mice + ODQ and 
DDAH1tg mice + ODQ (C). 
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Figure 15 A, B, C: Effect of ODQ on PAP of isolated lungs of WT & DDAH1tg mice during 
normoxic ventilation. Data are expressed as mean ± SEM (n=3 for each group); PAP: 
pulmonary artery pressure; WT: wild-type; DDAH1tg: dimethylarginine 
dimethylaminohydrolase 1 overexpressed; ODQ: 1H-[1, 2, 4]oxadiazolo[4, 3-a]quinoxalin-1-
one;  min: minute; NOX: normoxia; µM: micromolar. 
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5.1.5 Weight of mice used in acute and sustained hypoxic & normoxic experiments 
There were no significant differences between the weights of mice that were used in the 
isolated lung experiments. Therefore PAP variation in the experiments can not be based on 
weight changes (Fig. 16).  
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Figure 16: Weight of mice used in acute and sustained hypoxic experiments, as well as 
normoxic experiments. Data are expressed as mean ± SEM (n=9 for WT HOX group, n=10 
for  DDAH1tg HOX group, n=6 for WT + ODQ group, n=5 for DDAH1tg + ODQ group, n= 7 
for WT + L-NNA group, n=7 for DDAH1tg + L-NNA group, n=3 for each NOX group); WT: 
wild-type; DDAH1tg: dimethylarginine dimethylaminohydrolase 1 overexpressed; ODQ: 1H-
[1, 2, 4]oxadiazolo[4, 3-a]quinoxalin-1-one; L-NNA: Nω-Nitro-L-arginine; NOX: normoxia; 
HOX: hypoxia; g: gram. 
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5.1.6 Weight changes of isolated mouse lungs 
There was no difference in the weight changes (referred to the start of the experiment after the 
steady state period) of isolated lungs during the time course of the experiments (Fig. 17), 
when comparing WT mice, DDAH1tg mice during acute and sustained hypoxic experiments 
(A), comparing WT mice, WT mice + L-NNA, DDAH1tg mice and DDAH1tg mice + L-NNA 
during hypoxia (B), comparing WT mice, WT mice + ODQ,  DDAH1tg mice and DDAH1tg 
mice + ODQ during hypoxia (C) comparing WT mice and DDAH1tg mice during normoxia 
(D), comparing WT mice, WT mice + L-NNA, DDAH1tg mice and DDAH1tg mice + L-NNA 
during normoxia (E) and comparing WT mice, WT mice + ODQ,  DDAH1tg mice and 
DDAH1tg mice + ODQ during normoxic experiments (F). 
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Figure 17 A, B, C, D, E, F: Weight changes of isolated mouse lungs. Data are expressed as 
mean ± SEM (n=9 for WT HOX group, n=10 for  DDAH1tg HOX group, n=6 for WT + ODQ 
group, n=5 for DDAH1tg + ODQ group, n=7 for WT + L-NNA group, n=7 for DDAH1tg + L-
NNA group, n=3 for each NOX group); WT: wild-type; DDAH1tg: dimethylarginine 
dimethylaminohydrolase 1 overexpressed; ODQ: 1H-[1, 2, 4]oxadiazolo[4, 3-a]quinoxalin-1-
one; L-NNA: Nω-Nitro-L-arginine; min: minute; NOX: normoxia; HOX: hypoxia; g: gram. 
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5.1.7 NO release into the perfusate of isolated lungs of WT and DDAH1tg mice 
There were no significant differences in NO metabolite levels between WT and DDAH1tg 
mice at min 10, 20, 35, and 45. However, at min 220 the level of NO metabolites was 
significantly increased in DDAH1tg mice compared to WT mice (Fig. 18). There were also no 
significant differences in the NO metabolite levels during the time course of the experiment in 
WT mice, however, in DDAH1tg mice NO metabolite levels were increased at 220 min HOX 
compared to the other time points. 
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Figure 18: NO concentrations in the perfusate of isolated lung experiments of WT and 
DDAH1tg mice. NO levels were significantly increased in DDAH1tg mice at min 220 
compared to WT mice. Furthermore, in DDAH1tg mice NO levels were significantly 
increased at 220 min HOX compared to the other time points. Data are expressed as mean ± 
SEM (n=4 mice for WT group, n=8 for DDAH1tg group); WT: wild-type; DDAH1tg: 
dimethylarginine dimethylaminohydrolase 1 overexpressed; HOX: hypoxia; NOX: normoxia; 
min: minute; ***P<0.001 compared to WT mice, # # # P<0.001 compared to DDAH1tg mice at 
the other time points. 
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5.1.8 cGMP concentrations in the perfusate of isolated lungs of WT and DDAH1tg mice  
As found in measurements of NO metabolites, cGMP levels in the perfusate of isolated lung 
were significantly increased at min 220 in DDAH1tg compared to WT mouse lungs, but no 
significant differences at the other time points between both mice types could be detected 
(Fig. 19). Also cGMP levels were not significantly changed in the time course of the 
experiment in WT mice, but DDAH1tg mice showed a significant increase at 220 min HOX 
compared to the other time points. 
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Figure 19: cGMP concentrations in the perfusate of isolated lung experiments of WT and 
DDAH1tg mice. cGMP levels in the perfusate were significantly increased at min 220 in 
DDAH1tg compared to WT mouse lungs. In addition, DDAH1tg mice showed a significant 
increase at 220 min HOX compared to the other time points. Data are expressed as mean ± 
SEM (n=5 mice for each group); WT: wild-type; DDAH1tg: dimethylarginine 
dimethylaminohydrolase 1 overexpressed; HOX: hypoxia; NOX: normoxia; min: minute; 
*P<0.05 compared to WT mice, # P<0.05 compared to DDAH1tg mice at the other time points. 
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5.1.9 ADMA concentrations in the perfusate of isolated lungs of WT and DDAH1tg mice  
ADMA levels in lung perfusate of DDAH1tg mice were significantly decreased at min 20, 45, 
and 220 compared to WT mice (Fig. 20). Additionally there was a significant increase in 
ADMA levels at 220 min HOX in WT and DDAH1tg mice compared to the other time points. 
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Figure 20: ADMA concentrations in the perfusate of isolated lung experiments of WT and 
DDAH1tg mice. There was a significant decrease in ADMA levels in lung perfusate of 
DDAH1tg at min 20, 45, and 220 compared to WT mice. Furthermore, there was a significant 
increase in ADMA levels at 220 min HOX in WT and DDAH1tg mice compared to the other 
time points. Data are expressed as mean ± SEM (n=8 mice for each group); WT: wild-type; 
DDAH1tg: dimethylarginine dimethylaminohydrolase 1 overexpressed; HOX: hypoxia; NOX: 
normoxia; min: minute; *P<0.05, **P<0.005 compared to WT mice,   P<0.05 compared to 
DDAH1tg mice at the other time points, # P<0.05 compared to WT mice at the other time 
points. 
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5.2 Chronic hypoxic experiments 
In the following experiments WT and DDAH1tg mice were exposed to 3 weeks of hypoxia. 
For quantification of PH, RVSP, hematocrit and heart hypertrophy were determined. 
Furthermore, morphometrical changes of the pulmonary arterial vessels were investigated.  
 
5.2.1 RVSP in WT and DDAH1tg mice 
There was a significant elevation in WT and DDAH1tg mice exposed to 3 weeks hypoxia 
compared to their respective normoxic control groups with regard to RVSP (Fig. 21). RVSP 
showed no significant difference on exposure to chronic hypoxia in DDAH1tg compared to 
WT mice, there was no significant difference between both normoxic groups as well.  
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Figure 21: RVSP in WT and DDAH1tg mice. RVSP was significantly increased in hypoxic 
groups compared to their respective normoxic controls. Data are expressed as mean ± SEM 
(n=10 for each group); RVSP: right ventricular systolic pressure; WT: wild-type; DDAH1tg: 
dimethylarginine dimethylaminohydrolase 1 overexpressed; HOX: hypoxia; NOX: normoxia; 
*P<0.05 compared to respective normoxic control group. 
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5.2.2 Hematocrit values (%) in WT and DDAH1tg mice 
Hematocrit was significantly increased in hypoxic groups compared to their respective 
normoxic control in WT and DDAH1tg mice. Hematocrit showed no significant difference on 
exposure to chronic hypoxia in DDAH1tg compared to WT mice, and there was no significant 
difference between both normoxic groups (Fig. 22).  
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Figure 22: Hematocrit values in WT and DDAH1tg mice. Hematocrit value (%) was 
significantly increased in the hypoxic groups compared to their respective normoxic controls 
in WT and DDAH1tg mice. Data are expressed as mean ± SEM (n=10 for each group); WT: 
wild-type; DDAH1tg: dimethylarginine dimethylaminohydrolase 1 overexpressed; HOX: 
hypoxia; NOX: normoxia; **P<0.005 compared to respective normoxic control group. 
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5.2.3 Right heart hypertrophy  
Hypertrophy of the right ventricle of the heart was quantified as the ratio of the RV/(LV+S). 
This ratio was significantly increased after hypoxic exposure in WT and DDAH1tg mice 
compared to their respective normoxically ventilated controls. RV/(LV+S) showed no 
significant difference on exposure to chronic hypoxia in DDAH1tg compared to WT mice, 
furthermore, there was no significant difference between both normoxic groups (Fig. 23).  
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Figure 23: Values of RV/(LV+S) ratio in WT and DDAH1tg mice. The ratio of RV/(LV+S) 
was significantly increased in hypoxic groups compared to their respective normoxic controls. 
Data are expressed as mean ± SEM (n=10 for each group); WT: wild-type; DDAH1tg: 
dimethylarginine dimethylaminohydrolase 1 overexpressed; RV: right ventricle; LV: left 
ventricle; S: septum; HOX: hypoxia; NOX: normoxia; *P<0.05 compared to respective 
normoxic control group. 
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5.2.4 Weight of mice used in chronic hypoxic experiments 
As shown in Fig. 24, weight of mice was significantly decreased in the hypoxic groups 
compared to their respective normoxic controls in WT and DDAH1tg mice.  
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Figure 24: Weight of mice used in chronic hypoxic experiments. Weight of mice was 
significantly decreased in the hypoxic groups compared to their respective normoxic controls 
in WT and DDAH1tg mice. Data are expressed as mean ± SEM (n=10 for each group); WT: 
wild-type; DDAH1tg: dimethylarginine dimethylaminohydrolase 1 overexpressed; NOX: 
normoxia; HOX: hypoxia; g: gram; *P<0.05 compared to respective normoxic control group. 
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5.2.5 Degree of muscularization  
Exposure to 3 weeks hypoxia caused alterations in the muscularization of pulmonary arteries 
of different size in the different mouse strains: 
 - In small-sized (diameter 20-70 µm) pulmonary arteries, the portion of fully muscularized 
arteries in WT and DDAH1tg mice exposed to hypoxia was significantly increased compared 
to their respective normoxic groups. In parallel, the portion of non-muscularized pulmonary 
arteries in WT and DDAH1tg mice exposed to hypoxia was significantly decreased compared 
to their respective normoxic groups (Fig. 25). 
- In medium-sized (diameter 70-150 µm) pulmonary arteries, the portion of fully 
muscularized arteries in WT and DDAH1tg mice exposed to hypoxia was significantly 
increased when compared to their respective normoxic groups. In parallel, the portion of 
partially and non-muscularized pulmonary arteries was significantly decreased in WT and 
DDAH1tg mice exposed to hypoxia compared to their respective normoxic groups (Fig. 26). 
- In large-sized (diameter >150 µm) pulmonary arteries, the portion of fully muscularized 
arteries in WT and DDAH1tg exposed to hypoxia was significantly increased compared to 
their respective normoxic groups. In parallel, the portion of non-muscularized pulmonary 
arteries had the tendency to be decreased in WT and DDAH1tg mice exposed to hypoxia 
compared to their respective NOX groups (Fig. 27). 
- In all pulmonary arteries, it was found that the portion of fully muscularized arteries in WT 
and DDAH1tg mice exposed to hypoxia was still significantly increased compared to their 
respective normoxic groups. Also, the portion of non-muscularized pulmonary arteries was 
still significantly decreased in WT and DDAH1tg mice exposed to hypoxia compared to their 
respective NOX groups. Furthermore, the portion of partially muscularized arteries in WT 
mice exposed to hypoxia was significantly decreased when compared to its normoxic group 
(Fig. 28).   
- The degree of muscularization of pulmonary arteries was determined in histological sections 
stained with an antibody against α-smooth muscle actin. Representative samples of sections of 
the different groups are given in Fig. 29. There was no muscularization in small arteries 
(diameter 20-70 µm) during normoxia in both WT mice (A) and DDAH1tg mice (B). 
However, after exposure to 3 weeks of hypoxia, pulmonary arteries became muscularized in 
DDAH1tg mice (D) and WT mice (C). 
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Figure 25: Degree of muscularization of pulmonary arterial vessels (diameter 20-70 µm). 
Data are expressed as mean ± SEM (n=10 for each group); WT: wild-type; DDAH1tg: 
dimethylarginine dimethylaminohydrolase 1 overexpressed; HOX: hypoxia; NOX: normoxia; 
***P<0.001 compared to the respective normoxic control group.  
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Figure 26: Degree of muscularization of pulmonary arterial vessels (diameter 70-150 µm). 
Data are expressed as mean ± SEM (n=10 for each group); WT: wild-type; DDAH1tg: 
dimethylarginine dimethylaminohydrolase 1 overexpressed; HOX: hypoxia; NOX: normoxia; 
*P<0.05, **P<0.005, ***P<0.001 compared to the respective normoxic control group.  
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Figure 27: Degree of muscularization of pulmonary arterial vessels (diameter >150 µm). 
Data are expressed as mean ± SEM (n=10 for each group); WT: wild-type; DDAH1tg: 
dimethylarginine dimethylaminohydrolase 1 overexpressed; HOX: hypoxia; NOX: normoxia; 
*P<0.05 compared to respective normoxic control group. 
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Figure 28: Degree of muscularization of total pulmonary arterial vessels. Data are expressed 
as mean ± SEM (n=10 for each group); WT: wild-type; DDAH1tg: dimethylarginine 
dimethylaminohydrolase 1 overexpressed; HOX: hypoxia; NOX: normoxia; *P<0.05, 
***P<0.001 compared to respective normoxic control group. 
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Figure 29: Morphometrical analysis in WT and DDAH1tg mice. The pictures show the degree 
of muscularization of pulmonary arteries from WT (A) and DDAH1tg mice (B) exposed to 
normoxia and from WT (C) and DDAH1tg mice (D) exposed to hypoxia for 3 weeks. 
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6. DISCUSSION 
 
This study showed the impact of DDAH1 overexpression on the acute and sustained phase of 
HPV, as well as on the effects of chronic hypoxia on the pulmonary vasculature. DDAH1 
degrades ADMA, which is the most important endogenous NOS inhibitor and has been 
suggested to serve as a biomarker of endothelial dysfunction in many diseases such as PAH. 
This study showed that: 
1) Acute HPV is not affected by DDAH1 gene overexpression. Similarly perfusate levels of 
NO and cGMP are not altered in acute hypoxia, however, perfusate ADMA levels were 
decreased in perfused lungs from DDAH1tg mice without effect on NO, cGMP or vascular 
tone. 
2) Sustained HPV is decreased in DDAH1tg mice. Inhibitor studies revealed, that the 
attenuation is mediated by the NO-cGMP pathway, fitting to increased perfusate levels of NO 
and cGMP and decreased levels of ADMA in DDAH1tg mice compared to WT mice after 3 h 
of hypoxic ventilation.  
3) Chronic hypoxia-induced PH was not altered in DDAH1tg mice. 
 
6.1 Effects of DDAH1 on acute hypoxic response 
During acute HPV this study showed no differences in the level of PAP between DDAH1tg 
and WT mice. Also, administration of L-NNA, which is a NOS inhibitor, at a dose of 400 
µM, or ODQ, which is a sGC inhibitor, at a dose of 10 µM, in isolated lungs had no effect on 
HPV in both WT and DDAH1tg during this phase. This is in contrast to another investigation, 
showing that gene deletion of eNOS results in augmentation of HPV 76. The lower level of 
hypoxia (0% O2 in ventilated air) used in this study might be one reason for the discrepancy. 
Supportive for the finding of this thesis is the fact, that the acute hypoxic response in the 
eNOS knock-out mice was only influenced to a minor degree. In different species NO might 
be more potent during acute HPV, as inhibition of NO production in rabbits resulted in a large 
enhancement of HPV 117. Furthermore, the finding that the NO-cGMP pathway mediated 
vasodilation does not decrease acute HPV is supported by a study showing that sGC-α1 
deficiency does not change the response to acute hypoxia in lungs of anesthetized mice 109. 
Additionally it had been shown, that acute HPV is only influenced to a minor degree by the 
endothelium in isolated pulmonary arteries 118. 
The insensitivity of acute HPV to DDAH1 gene overexpression is also supported by the 
findings of the investigations regarding vasoactive substances in the perfusate. During 
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normoxia and acute hypoxia, NO and cGMP levels in the perfusate of isolated lungs were 
unchanged when comparing DDAH1tg and WT mice. However, the level of ADMA was 
decreased in DDAH1tg mice compared to WT mice. As DDAH1 degrades ADMA this effect 
could be expected. However, it remains unclear, why the decreased ADMA levels have no 
impact on the concentration of NO. This could be explained by other vasoactive mediator 
pathways that counterregulate NO concentration under this condition, e.g. increased NO 
synthase activity or compensatory downregulation of DDAH2.  
In summary, this study provides evidence that DDAH1 gene overexpression does not affect 
acute HPV. Furthermore, acute HPV in the isolated mouse lung is not regulated by inhibitors 
of the NO-cGMP pathway  
 
6.2 Effects of DDAH1 on sustained phase of HPV 
Application of 3 hours hypoxia in isolated perfused and ventilated mouse lungs resulted in a 
biphasic vasoconstrictive response. This response consisted of two phases: the first phase was 
a rapid, transient (5-10 min) increase in PAP which then decreased, but did not reach the basal 
level. This phase was followed by the second or sustained phase which was a more slowly 
developing, but sustained increase in PAP.  
The three hour hypoxic ventilation period was preceded by an acute hypoxic challenge. This 
protocol was chosen to confirm reproducible vasoreactivity of the pulmonary vasculature to 
the hypoxic stimulus in the initial phase of lung perfusion for each individual lung. This 
allowed assuring vascular reactivity of the explanted organ in the normal range. From 
previous (unpublished experiments) it is known that the preceding short term hypoxic 
ventilation does not affect the strength and time course of the subsequent response to 
sustained (2-3 hours) of hypoxia. This can also be expected from a teleologic point of view as 
acute HPV is a physiologic response to adapt blood flow to alveolar ventilation in an 
immediate ("from breath to breath") and fully reversible manner. In line with these 
characteristics of acute HPV, the vascular response to acute hypoxia was completely 
reversible in the current investigation as PAP returned to baseline when switching from ten 
minutes hypoxic ventilation to normoxia. This observation of the present study is also in line 
with the complete reversibility and high reproducibility of the HPV response during repetitive 
hypoxic ventilation maneuvers 115. Thus, a modulating effect of a preceding acute hypoxic 
ventilation on the subsequent sustained HPV can be excluded - also as the chosen hypoxic 
ventilation is, in contrast to e.g. ischemic/hypoxic damage in other organs induces a 
physiological, reversible response. 
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The biphasic response to sustained hypoxia has been described before in isolated lungs 26, 
isolated pulmonary arteries 24, and even isolated PASMC 119, however, it was also challenged 
by other investigators finding only monophasic responses 120, 121. 
This discrepancy might be due to the degree of hypoxia and pre-stimulation. The first phase 
of the constriction might not be limited to pulmonary arteries, because it was also observed in 
a variety of isolated systemic arteries 22, 122, 123. Thus the second phase of the vasoconstriction 
which is restricted to arteries of pulmonary origin 124 had been suggested to be the 
physiologically more important process for HPV 125, 126. Whereas acute HPV is thought to be 
mediated by a calcium increase in PASMC, sustained HPV has been shown to rely on a 
calcium sensitization of the myofilaments, possibly via phosphorylation by Rho-kinase 25, 28, 
29
.  
Although there is no complete consensus, if the sensitization mechanism is mediated by the 
endothelium, it was shown in most, but not all studies, that the full expression of sustained 
HPV requires an intact endothelium 22, 27, 127-129. DDAH1 overexpression in the DDAH1tg 
mice used in this study is driven by a human β-actin promoter and thus occurs in a tissue- and 
cell type-unspecific manner 130. However, as DDAH1 promotes NO production (see below) 
and main NO production in the lung occurs in the endothelium 131, the finding of this thesis, 
that the second phase of sustained HPV is completely abolished in isolated lungs of DDAH1tg 
mice, supports the important role of the endothelium for sustained HPV.  
As possible mediators, the increased production of NO in DDAH1tg mice may play a role, as 
DDAH1 inhibits ADMA which is an endogenous NOS inhibitor. Thus the net result of 
overexpression of DDAH1 would be an increased production of NO. From this study, this 
hypothesis is supported by the fact that 1) the difference of the second phase in DDAH1tg 
mice was reversed after the application of the NOS inhibitor L-NNA in WT and DDAH1tg 
mice and 2) the level of NO metabolites in perfusate was increased in DDAH1tg mice 
compared to WT mice. NO is considered as the major endothelium-derived vasoactive factor 
and is synthesized from oxygen and L-arginine by a family of three NO synthases, all of 
which are expressed in the lung 132. Endothelial NOS plays an important role in maintaining 
low pulmonary vascular tone 76. NO activates sGC which results in activation and synthesis of 
the second messenger cGMP which in turn activates cGMP-dependent protein kinases 
(protein kinases G) leading to reduction in cytosolic Ca2+ concentration and inhibition of the 
actin-myosin contractile system. This leads to vascular smooth muscle relaxation, inhibition 
of thrombocyte activity and decreased cell proliferation 77. The action of NO can be inhibited 
by 1) NOS inhibition either endogenously by ADMA and L-NMMA or pharmacologically by 
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L-NNA 2) sGC inhibitors such as ODQ and 3) PDE enzymes, which can exist in several 
isoforms and metabolize cGMP 133.  
Lung NO is the most important vasodilator and contributes to the amelioration of PH 128. It 
has been reported, that inhibition of EDRF-NO synthesis potentiates HPV both in vivo and in 
perfused lungs 129. This fits to the findings of this thesis, that the pulmonary vasoconstriction 
was increased during sustained hypoxic ventilation in presence of L-NNA in both, WT and 
DDAH1tg mice, even though in WT mice only significantly between minutes 15 to 85 of the 
hypoxic ventilation period. Moreover, in presence of L-NNA, overexpression of DDAH1 
resulted no longer in decreased HPV compared to WT mice. Therefore the difference in both 
mouse strains can be explained by an increased NOS activity in DDAH1tg mice. Furthermore, 
the application of the sGC inhibitor ODQ resulted in a similar increase of PAP in DDAH1tg 
mice as observed with L-NNA treatment. Therefore it can be proposed, that the increased 
levels of NO in DDAH1tg mice caused vasodilation via cGMP-dependent pathways. The 
relevance for cGMP-dependent pathways is emphasized by the finding that the level of cGMP 
in lung perfusate was strongly increased at the time point of sustained hypoxic ventilation in 
isolated lungs of DDAH1tg mice, being in line with the inhibition of vasoconstriction. 
Concentration of cGMP was more than 2-fold higher in DDAH1tg than in WT mice similar to 
the concentration of NO, a finding that again fits to activation of the NO-cGMP pathway as an 
underlying mechanism for the decreased HPV in DDAH1tg mice. However, DDAH1tg mice 
showed significantly lower PAP at late time points of hypoxic ventilation than WT mice in 
presence of ODQ.  
One explanation for this effect might be an incomplete inhibition of sGC in DDAH1tg mice 
based on the fact, that sGC is highly activated in DDAH1tg mice due to high NO 
concentration. On the other hand sGC could be activated in WT mice by NO-independent 
mechanisms to a higher degree than in DDAH1tg mice which would result in stronger relief of 
the vasodilative action of sGC during inhibition. However, activation of cGMP-independent 
pathways by NO in DDAH1tg mice, which may involve nitrite or reactions of NO with protein 
thiols to form S-nitrosothiols 134, as well as interaction of NO with mitochondria resulting in 
vasoactive effects 135, can not be excluded. When comparing the effects of L-NNA and ODQ 
in WT mice, it becomes evident that ODQ only enhances late time points of HPV, in contrast 
to L-NNA that significantly enhances early time points. This supports the conclusion that sGC 
could be activated by NO-independent mechanisms in WT mice 136 and NO may have a 
cGMP-independent vasodilative effect in WT mice as suggest in the DDAH1tg mice.  
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In contrast to NO and cGMP, the level of ADMA was highly decreased at all time points of 
sustained hypoxia in DDAH1tg compared to WT mice. At the end of the 3 hours hypoxic 
ventilation period, the level of ADMA was approximately lowered by about 65% in DDAH1tg 
compared to WT mice. The inverse correlation between ADMA levels and DDAH1 
overexpression is confirmed by a lot of studies such as the study of Dayoub et al. who have 
generated transgenic mice that overexpress the human isoform of DDAH1. These mice 
exhibited greater tissue DDAH activity and reduced plasma ADMA levels 130. The 
discrepancy between the decreased level of ADMA and unchanged NO, as well as cGMP 
levels in normoxia and acute hypoxia could be explained by compensatory downregulation of 
NO production in DDAH1tg mice, as discussed above. It should be pointed out as well that 
cGMP and NO levels show the tendency to be increased in acute hypoxia, but may not have 
accumulated enough in the measurement period to be significantly changed or cause 
vasodilatation. This may be different in the vivo situations.  
Interestingly, ADMA was increased in WT mice after 3 hours of hypoxic ventilation, in 
contrast to NO and cGMP. It remains to be elucidated, how the unchanged levels of NO and 
cGMP can be achieved in face of increased ADMA levels. Possibly, after 3 hours hypoxic 
ventilation, pathways that increase NO and cGMP levels were activated, but compensatory 
increase of ADMA kept NO and cGMP concentrations at the same level as during normoxic 
ventilation. However, it has to be kept in mind, that ADMA also could exert vasoconstrictive 
properties via NO-cGMP-independent mechanisms, that might be responsible specifically for 
sustained HPV. Moreover, perfusate levels of ADMA, NO and cGMP may only partially 
reflect cellularly active levels of these substances. As a future perspective, the mechanism of 
the increase in ADMA should be investigated, as possible connections to the suggested ROS 
pathway of HPV might exist 117, 137-139.  
Finally, the differences in sustained HPV in the described groups could not be attributed to 
variations in lung weight. Although there was a tendency to a decrease in lung weight changes 
in experiments with inhibited NO-cGMP pathway compared to non-treated groups, these 
alterations did not correlate to differences in sustained HPV. Moreover, the effects of DDAH1 
overexpression, L-NNA and ODQ were specific for hypoxia, as no differences in normoxic 
PAP recordings could be detected between these experimental groups and untreated controls. 
In summary this study revealed that the overexpression of DDAH1 results in the decrease of 
the sustained phase of HPV via NO-cGMP-dependent pathways. Increased ADMA levels 
might play a role in the regulation of sustained HPV in WT mice. 
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6.3 Chronic hypoxic exposure 
Exposure to chronic hypoxia induces structural and functional changes in the pulmonary 
arterial bed 84, 140. These changes include proliferation and migration of smooth muscle cells, 
as well as an increased accumulation of extracellular matrix.  
In the present study after exposure of mice to 3 weeks of chronic hypoxia, there was 
development of PH as specified by significantly increased right ventricular pressure, right 
heart hypertrophy and vascular remodelling in WT mice and DDAH1tg mice. However, there 
were no significant differences detected between WT mice and DDAH1tg mice. This would 
have been anticipated, as ADMA and NO which are both regulated by DDAH play an 
important role in PH. 
Hypoxia can inhibit the uptake of the NO precursor L-arginine by pulmonary arterial 
endothelial cells within 4 hours and may suppress the expression of NO synthase and activity 
79,  141, 142
. NO, synthesized by endothelial NO synthase, is a potent vasodilator and is 
considered to play an important role in regulating pulmonary vascular tone 79, 84. NO is the 
only known dilator that specifically suppresses HPV 81 and to which the vascular responses to 
chronic hypoxia have partially been attributed 83. Therefore, reduced production of NO in 
endothelial cells of the pulmonary arteries contributes to the progression of PH. The 
promotion of endogenous NO production in endothelial cells of the pulmonary arteries could 
be used as a therapeutic strategy in PH 143. 
NO production is regulated by endogenous NOS inhibitor ADMA. It was found that a marked 
increase in plasma ADMA levels accompanied hypoxia-induced experimental PH 144. The 
role of ADMA in PH of other etiologies has also been investigated, and patients with 
idiopathic PH were found to have higher plasma ADMA levels than healthy controls 145. Most 
importantly, the expression of PRMT, which synthesize ADMA, was found to be upregulated 
in mice exposed to chronic hypoxia, resulting in increased ADMA tissue levels and a 
decreased L-arginine/ADMA ratio, thereby supporting an important role of PRMT-mediated 
ADMA generation in hypoxia-induced PH 146. Furthermore, it has been reported that the 
levels of ADMA were highly increased in monocrotaline-induced PH in rats 147. ADMA is 
degraded by DDAH1 which therefore might also play a role in development of hypoxia-
induced PH. The activity of DDAH enzyme in the lungs was decreased in chronic hypoxia-
induced PH. This might be a result of the corresponding decrease in the protein expression of 
the DDAH1 isoform. Furthermore, the expression of the DDAH1 isoform was inhibited upon 
exposure to hypoxia, thus increasing ADMA levels 101. 
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However, we could find no significant difference in development of PH induced by hypoxia 
in DDAH1tg mice compared to WT mice. Overexpression of DDAH1 enzyme resulted only in 
the small tendency to decreased RVSP in hypoxic DDAH1tg mice by 5% compared to WT 
mice exposed to chronic hypoxia. In parallel, RV/(LV+S) ratio had the tendency to be 
decreased in DDAH1tg mice compared to WT mice exposed to chronic hypoxia.  
The most common feature of all forms of PH is the increase in the thickness of the medial 
layer of the normal muscular arteries and an extension of muscle into smaller and more 
peripheral vessels. In hypoxic WT and DDAH1tg mice, the portion of fully muscularized 
pulmonary arteries was significantly increased compared to their respective normoxic groups. 
Furthermore, the portion of non-muscularized pulmonary arteries was significantly decreased 
compared to their respective normoxic groups. Although the total percentage of fully 
muscularized pulmonary arteries in DDAH1tg mice exposed to 3 weeks hypoxia had the 
tendency to be decreased by 8% compared to hypoxic WT mice, there was also no significant 
difference in vascular remodelling quantified by morphometry between both mouse strains. 
The failure of DDAH1tg to inhibit development of hypoxia-induced PH, although it inhibits 
sustained HPV, might be due to the fact that different mechanisms may regulate HPV and 
pulmonary vasculature responses to chronic hypoxia 148. Specifically DDAH2 might be more 
important in the development of PH than DDAH1 147. In the DDAH1tg mice increased levels 
of DDAH1 activity might be opposed by counterregulation of vasoconstrictive pathways, as 
observed in normoxia in DDAH1tg mice, in which decreased ADMA levels were not reflected 
by increased NO or cGMP concentrations. Furthermore, the NO-cGMP pathway is already 
compensatory activated in chronic hypoxia 149, so that further activation by DDAH1 
overexpression might not be possible. 
 
In conclusion, the data of the present study provide evidence for the conclusion, that DDAH1 
specifically regulates sustained HPV via ADMA signalling. DDAH1 overexpression 
specifically inhibits sustained HPV through ADMA/NO-dependent pathways. This conclusion 
is supported by the finding that 1) DDAH1 overexpression decreased levels of ADMA 
compared to WT mice, increased NO concentration compared to WT mice in hypoxia and 
completely inhibited sustained HPV and 2) 3 hours exposure to hypoxia increased ADMA 
levels in WT mice, but not in DDAH1 overexpressing mice.  
Getting insight into DDAH1-dependent mechanisms may help finding new strategies for 
therapeutic intervention in HPV via controlling the NO pathway which plays an important 
role in the regulation of sustained HPV and PH. Possible cGMP-independent signalling of 
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DDAH1, counterregulatory mechanisms existing in the DDAH1 overexpressing mouse strain 
and upstream pathways of DDAH1/ADMA regulation should be addressed in further studies. 
NOS
L-arginine
sGC
DDAH1 overexpression
L-citrulline
Methylated protein
PRMT
ADMA 
NO 
GTP cGMP
No effect on acute
HPV
Inhibition of sustained HPVNo change in hypoxia-
induced PH
Vasodilatation
 
Figure 30: Effects of DDAH1 overexpression on alterations of the pulmonary vasculature 
induced by acute, sustained and chronic hypoxia. Overexpression of DDAH1 results in a 
complete inhibition of sustained hypoxia-induced pulmonary vasoconstriction, however, it has 
no effect on acute HPV or chronic hypoxia-induced PH. PRMT: protein arginine 
methyltransferase; DDAH1: dimethylarginine dimethylaminohydrolase 1; ADMA: 
asymmetric ω- NG, NG-dimethylarginine; NOS: nitric oxide synthase; NO: nitric oxide; sGC: 
soluble guanylyl cyclase; GTP: guanosine triphosphate; cGMP: cyclic 3', 5'-guanosine 
monophosphate; PH: pulmonary hypertension; HPV: hypoxic pulmonary vasoconstriction. 
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7. SUMMARY 
 
Hypoxia is a prominent factor for induction of pulmonary vasoconstriction and pulmonary 
hypertension (PH). Hypoxic pulmonary vasoconstriction (HPV) can be induced by alveolar 
hypoxia lasting seconds to minutes (= acute HPV) or minutes to hours (= sustained HPV). 
Both phases of HPV play an important role in matching local perfusion to ventilation, thus 
optimizing pulmonary gas exchange. However, the irreversible increase of pulmonary arterial 
pressure (PAP) induced by sustained HPV might also facilitate development of PH. PH is a 
fatal disease characterized by increased pulmonary vascular resistance. The pathophysiology 
of PH can include endothelial dysfunction and pulmonary arterial smooth muscle cell 
hypertrophy and proliferation. Nitric oxide (NO) is a well-known vasodilator controlling a 
diverse range of pulmonary functions such as regulation of PAP. Asymmetric ω- NG, NG-
dimethylarginine (ADMA) is a potent inhibitor of all three nitric oxide synthase (NOS) 
isoforms, resulting in impaired NO production. ADMA is degraded by dimethylarginine 
dimethylaminohydrolase (DDAH) 1 and 2, both expressed in the lung. 
Therefore, the current study investigated the effects of DDAH1 on acute and sustained HPV 
as well as on hypoxia-induced PH in isolated, ventilated and perfused mouse lungs, and in a 
whole animal model. PH was quantified by measurement of right ventricular systolic 
pressure, right-to-left heart ratio and vascular morphometry. Concentration of ADMA and 
cyclic 3', 5'-guanosine monophophate (cGMP) was determined by enzyme linked 
immunosorbent assay (ELISA). NO was measured by a chemiluminescence analyzer. 
DDAH1 overexpression had no effects on acute HPV. However, in sustained HPV (3 hours of 
hypoxia), DDAH1 overexpression abolished the increase in PAP almost completely and 
concomitantly decreased levels of ADMA, and significantly increased levels of NO and 
cGMP compared to wild-type (WT) mice. Sustained HPV could be restored by application of 
the NOS inhibitor Nω-Nitro-L-arginine (L-NNA), and the soluble guanylyl cyclase (sGC) 
inhibitor 1H-[1, 2, 4]oxadiazolo-[4, 3-a]quinoxalin-1-one (ODQ). Chronic hypoxic exposure 
(10% O2, 3 weeks) induced PH in WT and DDAH1tg mice without a difference in the degree 
of PH in both mouse strains.  
This study revealed, that DDAH1 regulates ADMA concentration, NO bioavailability and 
vessel tone specifically in sustained HPV. Therefore, getting insight into DDAH1-dependent 
mechanisms may help find new strategies for treatment of diseases with impaired ventilation-
perfusion matching due to decreased sustained HPV.  
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8. ZUSAMMENFASSUNG 
 
Hypoxie ist einer der häufigsten Faktoren, die zu pulmonaler Vasokonstriktion und 
pulmonaler Hypertonie (PH) führen. Die hypoxische pulmonale Vasokonstriktion (HPV) wird 
durch alveoläre Hypoxie induziert, die einige Sekunden bis Minuten (= akute HPV) oder 
Minuten bis Stunden (= prolongierte HPV) dauern kann. Beide Phasen der HPV spielen eine 
wichtige Rolle für die Anpassung der lokalen Perfusion an die alveoläre Ventilation und 
optimieren somit den pulmonalen Gasaustausch. Der Anstieg des pulmonalarteriellen Druckes 
(PAP), der durch die prolongierte HPV induziert wird, steht jedoch in der Diskussion, auch 
die Entwicklung von chronischer PH zu fördern. PH ist eine häufig tödlich verlaufende 
Erkrankung, die durch einen permanent erhöhten pulmonalvaskulären Widerstand 
charakterisiert ist. Die Pathophysiologie kann endotheliale Dysfunktion und Hypertrophie und 
Proliferation von pulmonalarteriellen glatten Muskelzellen umfassen. Stickstoffmonoxid 
(NO) ist ein bekannter Vasodilatator, der eine Vielzahl pulmonaler Funktionen kontrolliert 
und unter anderem in die Regulation des PAP involviert ist. Asymmetrisches Dimethylarginin 
(ADMA) ist ein hochpotenter Inhibitor von allen Isoformen der NO Synthase (NOS), und  
schränkt somit die NO Produktion ein. ADMA wird von den Dimethylarginin 
Dimethylaminohydrolasen (DDAH) 1 und 2 abgebaut, die beide in der Lunge exprimiert 
werden.  
Vor diesem Hintergrund untersuchte die vorliegende Studie die Effekte der DDAH1 auf die 
akute und prolongierte HPV und hypoxie-induzierte PH in der isolierten, ventilierten und 
perfundierten Mäuselunge, bzw. im intakten Tier. Die PH wurde mittels Messung des 
rechtsventrikulären systolischen Druckes, des Gewichtsverhältnisses von rechtem zum linkem 
Ventrikel und der vaskulären Morphometrie quantifiziert. Die Konzentration von ADMA und 
zyklischem Guanosinmonophosphat (cGMP) wurde mittels enzymgekoppeltem 
Immunadsorptionstest (EIA) bestimmt. NO wurde mit einem Chemilumineszenz-Analysator 
gemessen. 
DDAH1-Überexpression hatte keine Effekte auf die akute HPV. Allerdings war in 
prolongierter HPV nach 3 Stunden Hypoxie die Erhöhung des PAP bei DDAH1 
Überexpression komplett aufgehoben und gleichzeitig waren die Perfusatspiegel von ADMA 
erniedrigt und von NO und cGMP signifikant erhöht. Die prolongierte HPV konnte durch die 
Applikation des NOS Inhibitors Nω-Nitro-L-arginine (L-NNA), und den Inhibitor der 
löslichen Guanylatcyclase (sGC), 1H-[1, 2, 4]oxadiazolo-[4, 3-a]quinoxalin-1-one (ODQ), 
wiederhergestellt werden. Exposition chronischer Hypoxie (10% O2, 3 Wochen) führte zur 
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Entwicklung von PH in WT und DDAH1tg Mäusen, ohne einen Unterschied in der 
Ausprägung der PH in beiden Mauslinien.  
Die Studie zeigte, dass die DDAH1 die ADMA Konzentration, die NO Bioverfügbarkeit und 
den Gefässtonus spezifisch während der prolongierten HPV reguliert.  
Ein besseres Verständnis des DDAH1 Stoffwechselweges könnte dabei helfen, neue 
therapeutische Möglichkeiten bei Erkrankungen mit eingeschränkter Ventilations-Perfusions- 
Anpassung aufgrund erniedrigerter prolongierter HPV zu finden.  
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10. APPENDIX 
 
10.1 Statement/Erklärung an Eides Statt 
Hereby, I declare on oath, that the thesis “Hypoxia-dependent mechanisms in the pulmonary 
circulation - Role of dimethylarginine dimethylaminohydrolase 1 (DDAH-1) in acute, 
sustained and chronic hypoxia” is the product of my original research, and I did not use other 
sources or methods than those I have cited. In addition, I declare that this thesis is not 
submitted to any another evaluation, neither in this form nor in another. 
I have not acquired or tried to acquire any other academic degree than that documented in the 
application. 
 
“Ich erkläre: Ich habe die vorgelegte Dissertation selbständig, ohne unerlaubte fremde Hilfe 
und nur mit den Hilfen angefertigt, die ich in der Dissertation angegeben habe. Alle 
Textstellen, die wörtlich oder sinngemäß aus veröffentlichten oder nicht veröffentlichten 
Schriften entnommen sind, und alle Angaben, die auf mündlichen Auskünften beruhen, sind 
als solche kenntlich gemacht. Bei den von mir durchgeführten und in der Dissertation 
erwähnten Untersuchungen habe ich die Grundsätze guter wissenschaftlicher Praxis, wie sie 
in der ”Satzung der Justus Liebig Universität Gießen zur Sicherung guter wissenschaftlicher 
Praxis” niedergelegt sind, eingehalten“. 
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